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National Drugs Conference 2010
The fi rst Irish National Drugs Conference will be held on 4–5 
November 2010 at the Radisson Blu Royal Hotel, Dublin 8. It is 
being organised by the Irish Needle Exchange Forum (INEF) in 
association with the Irish Association of Alcohol and Addiction 
Counsellors, Ana Liffey Drug Project and Coolmine Therapeutic 
Community. The theme of the conference is ‘A continuum of care 
within drug services’.
The keynote speaker will be Dagmar Hedrich of the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 
Academics, practitioners and policy makers working in the drugs 
fi eld in Ireland and abroad will present papers and contribute to 
plenary sessions, workshops and other fora. Speakers will include 
Minister Pat Carey, Rowdy Yates (University of Stirling), Stephen 
Bamber (Liverpool Hope University), Dr David Best (University of 
Western Scotland), Dr Scott Kellogg (New York University), Mat 
Southwell (INPUD), Dr Brion Sweeney, Dr Joe Barry, Professor 
Pat O’Hare, and Austin Prior (Rutland Centre).
A number of Health Research Board (HRB) research staff will present 
papers at the conference. Delphine Bellerose will report on an analysis 
of data from both the National Drug Treatment Reporting System 
(NDTRS) and the Drug-Related Deaths Index (NDRDI) used to describe 
trends in treatment for problem benzodiazepine use and to develop 
a profi le of benzodiazepine users. Anne Marie Carew will describe a 
study of treated problem substance use in the Traveller community, 
based on cases recorded on the NDTRS. Simone Walsh will describe 
the work of the NDRDI in providing a complete and accurate reporting 
of drug- and alcohol-related deaths and deaths among drug users and 
among those who are alcohol dependent. Dr Suzi Lyons will present an 
analysis of data from the NDRDI showing the incidence of drug-related 
death among individuals who have been released from prison.
Martin Keane will report on a qualitative synthesis of 
research on methadone treatment programmes which 
seeks to identify obstacles to progression faced by clients 
on such programmes. Brigid Pike’s paper will analyse the 
National Drugs Strategy 2001–2008 (NDS) as a policy 
instrument. It will explore how the NDS was designed 
and developed, and the strategic management processes 
and governance arrangements put in place to support 
implementation.
The National Drugs Conference 2010 is an excellent 
opportunity to bring together policy developers and 
practitioners from right across the drug treatment 
spectrum to share knowledge and develop networks. A 
limited number of delegate places remain. If you would 
like to attend the conference, consult the INEF website 
at www.inef.ie or email 2010@inef.ie 
(Brian Galvin)
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In March 2010, following a recommendation by 
the Special Group on Public Service Numbers 
and Expenditure Programmes (McCarthy report), 
the National Economic and Social Forum (NESF) 
was wound up. During its 16½ years the NESF, a 
government-appointed social partnership body, 
provided advice on economic and social policies, 
especially those intended to achieve greater 
equality and social inclusion in Irish society. 
Many of the NESF’s investigations infl uenced 
thinking with regard to policies to tackle the 
illicit drug problem, particularly in the areas of 
drug use prevention and rehabilitation. Relevant 
investigations included studies of early school 
leavers, lone parents, the long-term unemployed, 
prisoners, social housing, mental health, arts and 
cultural inclusion, and the policy implications of 
social capital. A number of these studies were 
reported on in Drugnet Ireland.
In recent years the NESF also began to explore 
issues around the implementation of policy and 
delivery of services, again with relevance to illicit 
drugs policy. With its diverse membership and 
experience of policy processes across institutional 
and departmental boundaries, the NESF was 
considered well positioned to identify innovations 
and reforms that would ensure that public services 
better met individual needs and were delivered 
more effectively.
In 2007 NESF Report No 34, Improving the delivery 
of quality services, put the citizen at the centre 
of public services reform, recommending a new 
‘public value’ approach for delivering quality 
public services. This approach would ensure 
people’s needs are better met and assist in the 
implementation of the ‘lifecycle’ approach to the 
future development of public services. The links 
between better public service delivery and equality, 
social inclusion and the rural/urban dimensions 
were strongly emphasised. 
Published in late 2009 and early 2010, the NESF’s 
last three reports – on implementing the Home 
Care Package scheme (Report No 38); child literacy 
and social inclusion policies (Report No 39); and 
a discussion report on community participation 
in the delivery of public services – addressed the 
issues associated with policy implementation. This 
body of work highlighted how good policies have 
had mixed success when implemented, because 
of the way policy actors think about risk and 
accountability, how they frame their own role and 
the role of others involved in the process, and how 
organisational cultures of defensiveness militate 
against learning.
The reports on implementing home care and child 
literacy policies proposed a ‘policy implementation 
template’ comprising the following items:
Strategy plans with agreed outcomes1. 
Delivery plans and delivery on the ground 2. 
(including standards, competition, co-
ordination of organisations and procedures and 
tailored universalism)
Monitoring, evaluation and measurement of 3. 
inputs, outputs and outcomes
Links between outcomes and budget4. 
Good accountability and incentive structure5. 
Equity in provision6. 
Cultural elements (including values, beliefs and 7. 
tacit assumptions, leadership, attitudes and 
quality of collaborative relationships)
The discussion report on local participatory 
governance provides a framework within which to 
understand the range of community participation/
governance arrangements currently in operation. 
A separate article on page 4 discusses this report in 
the context of the ongoing national debate on how 
to strengthen local democracy.
The activities of the NESF have been absorbed by 
the National Economic and Social Council (NESC), 
a constituent body of the statutorily-based National 
Economic and Social Development Offi ce (NESDO). 
To date, the function of the NESC has been to 
analyse and report to the Taoiseach on strategic 
issues relating to the effi cient development of the 
economy and the achievement of social justice and 
the development of a strategic framework for the 
conduct of relations and negotiation of agreements 
between the government and the social partners. 
The NESC is chaired by the secretary general of 
the Department of the Taoiseach and includes 
representatives of trade unions, employers, farmers' 
organisations, NGOs, key government departments 
and independent experts.
The NESF was the largest of the social partnership 
bodies. It comprised 60 social partners, 
representing employer, trade union and farming 
organisations, the community and voluntary 
sectors, members of the Dáil and Seanad, 
representatives of central and local government, 
and independent experts. In the fi nal newsletter 
of the NESF (February 2010), NESF Chairperson, 
Dr Maureen Gaffney, asserted that a unique 
feature of the NESF was its ‘strongly independent, 
consultative and participative ethos. It was open in 
a routine way to other actors in the system and to 
those working directly with people experiencing 
poverty and social exclusion. This way of working 
facilitated the early identifi cation of emerging 
trends in social exclusion, and of the glitches and 
failures in policies designed to address them.’ 
(Brigid Pike) 
For further information on the NESF and the NESC, 
and access to the reports, visit www.nesdo.ie 
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3The last issue of Drugnet Ireland reported on a recent study 
that sought to identify what constitutes the ‘evidence’ 
relating to the drugs problem and how one decides what is 
the ‘best’ evidence?1 Another recent publication explores the 
process rather than the content – how does evidence feed 
into policy?2 It draws together the lessons from six European 
countries, including Ireland. The authors of the article on the 
Irish experience identify four mechanisms that serve to ‘feed’ 
evidence into Ireland’s social policy development process in 
the health care sector:3 
social partnership,1. 
research producers for government, e.g. National Economic 2. 
and Social Council (NESC), National Economic and Social 
Forum (NESF) and Combat Poverty Agency (CPA),
academic research, and 3. 
professional associations.4. 
This list provides a useful starting point for considering the 
range and nature of ‘knowledge exchange’ mechanisms in 
the drug policy domain.
Ireland’s two national drugs strategies were developed 
using the social partnership approach, depending on 
public consultation meetings held throughout the country, 
written submissions, meetings with departments, statutory 
agencies, sectoral groups, organisations and focus groups, 
and engaging with the Oireachtas. Kennedy and colleagues3 
comment that, in the current economic climate, the social 
partnership model is under strain and whether or how it 
will continue to serve as a defi ning characteristic of policy 
development in Ireland is uncertain. 
‘Research producers for government’ have been another 
casualty of the current recession, with the work of the NESF 
and the Combat Poverty Agency being absorbed into the 
work of other entities. Notwithstanding the contribution that 
research published by both these bodies made to increasing 
understanding of the issues associated with problem drug 
use, an independent study of the overall impact of state 
agencies such as these concluded that their performance 
appeared ‘less than optimal, in terms of both their perceived 
effectiveness and the level of duplication and overlapping 
responsibilities’ (p. 130).4
With regard to academic research, Ireland has only one 
drug-related research centre – the Irish Focal Point (IFP) 
of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), located in the Health Research Board 
(HRB). Funded by the EMCDDA, the IFP compiles an annual 
report on the drug situation in Ireland and responses to it, 
and participates in EMCDDA-led data-gathering, analysis 
and dissemination projects in conjunction with focal points 
in other member states. The IFP draws on the drug-related 
epidemiological databases located in the HRB – the National 
Drug Treatment Reporting System (NDTRS) and the National 
Drug-Related Deaths Index (NDRDI) – for much of its work. 
While there is a paucity of dedicated drug-related research 
infrastructure, individuals in tertiary institutions across the 
island of Ireland, in academic disciplines ranging from 
medicine to pharmacology to criminology and sociology, 
undertake drug-related research. The database of current 
research and evaluation projects on the website of the 
National Documentation Centre on Drug Use indicates that 
a signifi cant proportion of drug-related research projects are 
funded either through state funding bodies such as the HRB, 
or commissioned by state agencies such as the Health Service 
Executive or the National Offi ce on Suicide Prevention.5
Finally, practitioners in specifi c callings relating to drugs 
and addiction have come together to form professional 
associations in Ireland, for example the Drug Education 
Workers Forum and the Irish Association of Addiction and 
Alcohol Counsellors (IAAAC). However, there is no umbrella 
organisation that brings together professionals and non-
professionals, academics, policy makers, public offi cials, 
and members of organisations under the social partnership 
pillars, to debate, discuss and contribute to developing 
thinking on drug policy in Ireland. A national conference on 
drugs, organised by a group of voluntary sector bodies, 
will be held in Dublin on 4–5 November 2010 (see article 
on p. 1). Such an event could be an opportunity to form an 
independent forum. 
One formal knowledge-exchange mechanism not described 
by Kennedy and colleagues but used in Ireland’s drugs 
policy domain is the National Advisory Committee on Drugs 
(NACD). Appointed by the Minister with responsibility 
for the National Drugs Strategy, the NACD includes 
representatives from academic disciplines, professional 
practitioners, civil and public servants, and representatives 
of the voluntary and community sectors. It advises the 
government on problem drug use in Ireland in terms of 
prevalence, prevention, consequences and treatment, based 
on its analysis and interpretation of research fi ndings; where 
it fi nds gaps in knowledge, it may commission research. 
While stipulating that the independence of the NACD’s 
research work would be ‘fully maintained’, the National 
Drugs Strategy 2009–2016 brought the NACD within 
the ambit of the new Offi ce of the Minister for Drugs. 
The intention was ‘to better address the issue of linkages 
between policy development and research’ (para. 6.74).6
(Brigid Pike)
See report on T Babor, J Caulkins J, G Edwards, B Fischer, 1. 
D Foxcroft, K Humphreys et al. (2010) Drug policy and 
the public good (Oxford: Oxford University Press) in 
Drugnet Ireland, (34): 11–12.
Nutley S, Morton S, Jung T and Boaz A (2010) Evidence 2. 
and policy in six European countries: diverse approaches 
and challenges. Evidence & Policy, 6(2): 131–144. The 
issue includes articles on evidence-based policy and 
practice in Iceland, Ireland, the Netherlands, Norway, 
Scotland and Sweden. 
Kennedy P, de Brun T, O’Reilly-de Brun M and 3. 
MacFarlane A (2010) An exploration of evidence-based 
policy in Ireland: health and social inclusion. Evidence & 
Policy, 6(2): 255–268. 
Quinn O (2008) 4. Advisers or advocates? The impact of 
state agencies on social policy. Dublin: Institute of Public 
Administration. 
www.drugsandalcohol.ie accessed on 30 June 2010 5. 
Department of Community, Rural and Gaeltacht Affairs 6. 
(2009) National Drugs Strategy (interim) 2009 – 2016. 
Dublin: Department of Community, Rural and Gaeltacht 
Affairs. Available at www.drugsandalcohol.ie/12388 
How does evidence feed into Ireland’s 
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local and community-level bodies, i.e. the governance 
framework, have attracted considerable attention in 
recent years. Following its establishment in 2002 the 
Department of Community, Rural and Gaeltacht Affairs 
undertook a ‘cohesion process’, whereby it signifi cantly 
reduced the number of community-based bodies involved 
in providing local and community development and social 
inclusion programmes while seeking to maintain service 
provision across the country. Most recently, in January 
2010, the Department merged its own two social inclusion 
programmes into one integrated programme – the Local 
and Community Development Programme (LCDP). In the 
drugs area, in the course of 2009, the work of the National 
Drugs Strategy Team, comprising representatives of 
relevant departments, state agencies and the voluntary and 
community sectors which supported the work of the local 
and regional drugs task forces, was absorbed into the Offi ce 
of the Minister for Drugs, which is located in the Department 
of Community, Equality and Gaeltacht Affairs.1
The assumptions underpinning these cohesion and 
rationalisation processes have recently been challenged in 
the National Economic and Social Forum’s fi nal report.2 
Exploring local participatory governance in Ireland, the 
authors argue that a certain level of seeming duplication is 
necessary to ensure that the complex array of needs and 
circumstances can be accommodated, and that ‘different 
opportunities for participation and, most importantly, for 
the realisation of social inclusion’ are provided. Mapping the 
landscape of participatory processes, they have divided it 
into four ‘zones’:
in-house participatory government, e.g. strategic policy 1. 
committees;
moving towards governance ‘out there’, e.g. county/city 2. 
development boards, RAPID;
participating governance ‘out there’, e.g. area-based/3. 
community partnerships, local and regional drugs task 
forces; and 
civil society organisations, e.g. community platforms.4. 
Rather than streamlining structures, collapsing the range of 
governance frameworks into a one-size-fi ts-all, the authors 
argue that greater attention should be given to supporting 
participation and to strengthening performance within 
each of the zones. In Zone 3, where the authors locate the 
drugs task forces, they suggest that participation could 
be enhanced by strengthening co-operation between the 
entities and elected local representatives, by promoting 
an approach to problem-solving based on reference to 
organisational values, such as social inclusion and fi nding 
a voice, rather than stressing rules and procedures, and by 
ensuring that the local development culture is not weakened.
The authors of the NESF report expressed the hope that 
their analysis might feed into deliberations leading to 
the development of the government’s White Paper on 
stronger local democracy. In the Green Paper published as a 
preliminary step towards this White Paper,3 the government 
has suggested that community participatory structures could 
be strengthened by giving local authorities the leadership 
role on the county/city development boards. Unlike single-
focus agencies, local authorities are regarded as having 
the fl exibility to be creative about new services they might 
provide. 
In a separate study, looking at how to promote innovation 
generally, Ireland’s National Economic and Social 
Development Offi ce (NESDO) organised a project, 
FuturesIreland, to investigate how to develop a capacity 
for foresight and innovation both in the Irish economy and 
society and in the nation’s decision-making processes – in 
short, how to turn Ireland into a ‘learning society’.4 The 
project reached four conclusions:
Cross-fertilisation between the economy, society 1. 
and public governance enhances the ability to learn 
and innovate.
Innovation and learning are systematic, almost always 2. 
combining initiative, disciplined review and a willingness 
to confront challenges – institutional, inter-personal 
and personal. 
Systematic review provides the basis for both innovation 3. 
and accountability.
Organisational systems, particularly systems of control and 4. 
accountability in the public sector, need to be completely 
changed in order to promote innovation and learning. 
SAOL – Service Provision for Women with Addiction 
Problems – based in inner-city Dublin was one of several 
case studies undertaken by FuturesIreland that led to the 
fourth conclusion. The authors described how the rapid 
change from heroin to crack cocaine use rendered many of 
SAOL’s services ineffective, causing the project to refocus 
its services very quickly. This was done following extensive 
consultations with colleagues in the Netherlands who were 
engaged in drug treatment services and had already dealt 
with this problem. SAOL piloted, tested and reviewed the 
new approach with women in their rehabilitation project. 
Notwithstanding this thorough review process, SAOL 
found it diffi cult to have the shift in focus accepted by their 
statutory funding body. FuturesIreland suggested that, ‘To a 
large degree, the difference between the staff delivering the 
service and the people in the funding body centred on the 
willingness, ability and familiarity with data and methods of 
review’ (p. 41). 
(Brigid Pike)
Department of Community, Rural and Gaeltacht Affairs 1. 
(2009) National drugs strategy (interim) 2009–2016. Dublin: 
Department of Community, Rural and Gaeltacht Affairs.
McInerney C and Adshead M (2010) 2. The challenge of 
community participation in the delivery of public services: 
exploring local participatory governance in Ireland. 
Dublin: National Economic and Social Forum. 
Department of the Environment, Heritage and Local 3. 
Government (2008) Stronger local democracy – options 
for change. Green Paper on Local Government. Dublin: 
Department of the Environment, Heritage and Local 
Government. 
FuturesIreland (2009) 4. Ireland at another turning 
point: reviving development, reforming institutions and 
liberating capabilities. Dublin: National Economic and 
Social Development Offi ce. Available at www.nesdo.ie/
futuresireland/futuresireland_fi nalreport0909.pdf
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in the Canal Communities area
In 1997, in response to the heroin problem, the 
Government set up 14 local task forces in the 
areas most affected. Task forces are partnerships 
between all interested stakeholders looking to bring 
a multi-agency response to the issue. The Canal 
Communities Local Drugs Task Force (CCLDTF) 
covers Rialto, Bluebell and Inchicore communities in 
the Dublin 8 area.
The CCLDTF undertook a study to improve 
knowledge and understanding of the nature of illicit 
drug use in their area.1 The researchers used an 
ethnographic method, which the authors state ‘can 
be defi ned as a perspective as well as a means of 
data collection’ (p. 12). Ethnographic studies aim to 
describe and explain how specifi c groups of people 
experience their lives and environment.2 
Data for the CCLDTF study were collected by means 
of participant observation (in service facilities, 
estates, homes) and through interviews. Fifty-one 
interviews were conducted, of which 24 were 
life histories and eight were group discussions 
(with 29 young people). Six of those who were 
initially interviewed had a subsequent interview. 
Additionally, there were 24 formal and informal 
interviews with service providers. The authors 
note that many other people interacted with the 
research at all the different sites. Interviewers also 
administered a survey to a target population of 100 
opiate or methadone users; some of the results of 
that survey appear in the text and the appendix 
(and will be discussed in more detail in a future 
CCLDTF publication). 
The report of the study begins with a discussion 
on the nature of drug use and the diffi culties in 
relation to the categorisations used within the 
fi eld. In relation to patterns of use, the authors 
use the term ‘styles’ as this can help convey how 
‘…at any one moment, populations that overlap 
certain institutional categories (disorganized heroin-
users, for example, can be found both in and out 
of treatment, often using both methadone and 
heroin simultaneously), while presenting different 
challenges to various intervention strategies’ (p. 
19). This is followed by a chapter which discusses 
experiences of the combined use of heroin and 
methadone in the CCLDTF area.
Subsequent chapters deal with the history and the 
issues around drug use in the area, the emergence of 
crack cocaine and the changing patterns of drug use. 
Data from the Central Treatment List (CTL) pertaining 
to people living in the CCLDTF area were analysed. 
One fi nding from this analysis was that the area had a 
relatively high rate of registration on the CTL in 2007, 
at 20 per 1,000 of the population, compared to 2 per 
1,000 of the population nationally. 
The quantitative data collected from 98 valid 
responses to the survey are summarised in an 
appendix to the report. The main results include:
63% were male;• 
98% were prescribed methadone;• 
Average number of days on methadone • 
was 86;
63% reported current use• 3 of heroin;
46% reported current use of street • 
benzodiazepine;
30% reported current use of crack;• 
22% reported current use of powder cocaine;• 
17% reported current use of street • 
methadone;
60% of those who injected reported sharing • 
a needle or syringe;
36% reported spending between • €60 and 
€119 on drugs in the average week;
88% reported ever having been involved • 
in crime;
57% reported having had a custodial • 
sentence.
While the authors concede that the methodology 
used made it diffi cult to summarise the report, 
they identify fi ndings that they felt were important 
(illustrated for the purposes of this article with extracts 
from the fi eld notes and interview transcripts).
Most of those interviewed were polydrug • 
users, often using combinations of illegal 
and legal drugs (whether obtained legally or 
not). Louise is on methadone and prescribed 
sleeping tablets and an antidepressant. She 
smokes a couple of bags of heroin every few 
days. Recently, she has been smoking crack 
every day. This is her main problem drug at 
the moment. Her weight loss is noticeable. 
(Field notes, p. 18)
Many of those in treatment for problem • 
opiate use had a range of unmet needs. 
Many of those who took part in the study • 
and who were in treatment for opiates also 
used cocaine, with the use of crack cocaine 
emerging as a problem. I got a pipe off 
someone and I says, ah that’s not doing me 
any harm, [be]cause it was really the needles 
[to inject cocaine] that was doing the harm, 
the blood poisoning, septicaemia, so I says ah 
I’ll have a pipe [of crack] and then I went to 
have another one, …going half with someone, 
and when I was going well, I would get one 
for meself. ‘Just one’, I’d say, ‘and I’ll go down 
and have a nice smoke at the end of the 
night,’ to meself. …and I was smokin’ every 
morning and all. (‘Sandra’, p. 42)
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after entering treatment.
Heroin use was viewed unfavourably by younger drug • 
users. You know what I mean, when you hear about 
new drugs coming out and all these mad trips and you’d 
say oh I have to try this, it’s an experience, but we never 
turn round and say, ‘I have to try heroin and see what 
that’s like’, d’ya know what I mean? (‘Kim’, p. 53)
While terms and categories used in government • 
policy such as ‘drug user’ and ‘treatment’ appear to 
be clearly defi ned, particularly as used in relation to 
funding, their application at local level is less clear, 
causing a ‘divide [that] needs to be bridged’. 
(Suzi Lyons)
Saris A J and O’Reilly F (2010) 1. A dizzying array of 
substances: an ethnographic study of drug use in the Canal 
Communities area. Dublin: CCLDTF. 
Available at www.drugsandalcohol.ie/13503
Robson C (2002) 2. Real world research. 2nd edition. 
Padstow: Blackwell Publishing. 
Current use is defi ned as use in the past three months.3. 
An ethnographic study of drug use in the Canal Communities area (continued)
Drug awareness initiatives in Fingal county
A combined launch and award ceremony in Wynne’s Hotel 
on 30 June illustrated the strong commitment and support 
for educational initiatives to tackle drug-related issues in the 
Blanchardstown and Fingal communities.
The event featured the two initiatives described below.
‘Let’s Talk About Drugs’ media awards
Greater Blanchardstown Response to Drugs (GBRD) 
presented the ‘Let’s Talk About Drugs’ 2010 media awards, 
with Councillor Ken Farrell, mayor of Fingal, attending. Now 
in their fourth year, these awards are organised by the GBRD 
in partnership with the Dublin People newspaper group, 
Blanchardstown Local Drugs Task Force, and County Dublin 
Vocational Education Committee (CDVEC). 
Phillip Keegan, co-ordinator of GBRD, briefl y described the 
media awards initiative: young students and adults with 
an interest in journalism are invited to research and write 
articles about one of two drug-related topics that are chosen 
each year. The aim is to trigger discussion, and therefore 
raise awareness, about drug-related issues in the community. 
The initiative also rewards sensitive and well-informed 
reporting on drugs and encourages budding journalists. 
Sean Mullan, chairperson of GBRD, pointed out that there is 
no better way to raise awareness than by using the media. 
The two topics for 2010 were ‘Head shops – legal but 
potentially fatal?’ and ‘Tackling drugs – the real cost of budget 
cuts’. The head shop topic was the most popular; all articles 
were written prior to the new legislation on legal highs. Phillip 
Keegan, along with many of the winners and other speakers 
on the day, reiterated that, despite the recent developments 
in the head shop debate, it is extremely important to remain 
vigilant to prevent head shops from going underground and 
to prevent new potentially dangerous substances from being 
made available in the community.
Jim McVeigh, youth development offi cer with CDVEC, 
presented some of the awards and emphasised the 
important educational aspect of the programme, by which 
students get hands-on experience in researching a topic and 
writing an article, and also learn and inform others about the 
important issue of drugs.
Jack Gleeson, news editor for Northside People West, 
stressed the overall good quality of all articles entered 
in the competition and congratulated the winners on 
their well-researched and well-written pieces of work. He 
mentioned that the media’s responsibility with regard to 
drugs and addiction is to change perceptions and challenge 
preconceived ideas.
Winners and runners-up in the youth categories got prizes of 
laptops and digital cameras. The winning articles are being 
published in the Northside People and Southside People 
newspapers throughout the summer, and are available on 
the GBRD website at www.gbrd.ie. The winners described 
the programme as an excellent experience, a great incentive 
to pursue their interest in writing and journalism, and a real 
eye-opener on drug issues.
The 2010 award winners were:
12–14-years: Rebecca Murphy, Rockford Manor 
Secondary School 
15–17-years: Lisa Murphy, Cabinteely Community School; 
Uzair Saif Qureshi, Institute of Education 
drugnet 
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Fingal, Councillor Ken Farrell, and GBRD personnel
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18–20-years: Sehreen Qureshi, Trinity College Dublin; Ian 
McFarlane, St Kevin’s College, Finglas 
21 years and over: Emer Halpenny, Independent College; 
Majella Twomey, Independent College 
Special Merit Award: Stuart Larner, Catholic University School 
Endeavour Award: Eoin Harty, Catholic University School 
‘Stay onside – say no to drugs’ initiative
The GBRD awards event was held in conjunction with 
the offi cial launch of a new drug awareness campaign by 
Sporting Fingal Community Trust, the charitable arm of 
Sporting Fingal Football Club (www.sportingfi ngal.ie). 
One of a series of projects being delivered jointly by the 
Club and the Community Trust, the ‘Stay onside – say no to 
drugs’ initiative is a drugs education ‘trading card’ scheme. 
It includes sets of collectable cards featuring player profi les 
with anti-drugs messages from members of the Sporting 
Fingal squad. The cards were produced by the Trust in 
conjunction with CDVEC. Sets of cards are being distributed 
to young people through schools and summer camps and at 
matches. The idea behind the scheme is that young people 
are more likely to be infl uenced by their local sporting 
heroes’ endorsement of healthy lifestyles. 
Councillor Ken Farrell, mayor of Fingal, and Brian Gannon, 
Sporting Fingal defender representing the squad, both 
emphasised the importance of sport as a powerful way 
to reach out to young people, to help people affected by 
drugs and, more generally, as ‘an excellent tool for building 
communities’.
(Delphine Bellerose)
Drugnet digest
This new feature of the newsletter will contain short 
summaries of recent research reports and other 
developments of interest.
Clinical audit of the ICGP Methadone Treatment Protocol
The fi ndings of the general clinical audit of the operation of the 
ICGP Methadone Treatment Protocol (MTP) between July and 
December 2009 are summarised in the most recent Methadone 
Treatment Protocol Newsletter.1 The audit found the most 
common issues that required a review were: vaccination and 
virology, record keeping and supervision of dispensing. The 
newsletter gives examples of discrepancies found between 
the standard expected and the actual practice among a small 
proportion of the GPs who participate in the MTP scheme, and 
suggests ways to improve practice in these areas. 
On transfer between Level 1 and Level 2 doctors, not • 
all clients had their virology screening or vaccination 
completed, as required by the protocol. In some cases, 
screening or vaccination history was not documented. 
Some cases transfer summaries were diffi cult to fi nd or • 
were missing, and not every consultation record was 
complete. 
In some cases where at least one supervised dose per • 
week in the pharmacy was the expected standard, no 
request for such supervision was found in the fi le. In 
some cases, ‘supervised dispensing did not appear to 
be responsive to clinical conditions’, for example in 
failing to provide for increased supervision if a client 
appeared to be destabilising.
Irish Prison Service annual report 2009
The Irish Prison Service (IPS) annual report for 20092 states that 
drug treatment continues to be one of the biggest issues facing 
the Irish prison health services. Those who present with a history 
of problem opiate use are offered detoxifi cation if it is clinically 
indicated, or methadone maintenance treatment. Those who 
are already on methadone when committed can continue to 
receive this treatment for the duration of their sentence. 
The number of prisoners on methadone treatment increased 
by 20% between 2008 and 2009. There was a 10% increase 
in the number of people new to treatment. Over 20% of those 
on the Central Treatment List (CTL) of methadone clients in 
2009 were treated within the IPS, and 31% of all new entrants 
on the CTL for 2009 were treated within the IPS. Since 2008, 
pharmacists have provided the methadone treatment in 
Mountjoy and in the Dóchas Centre. The report states that 
in 2009 the service continued to face challenges in securing 
places in methadone clinics in the community for prisoners 
who were due to be released. 
Detoxifi cation treatment was provided to 1,130 prisoners 
in 2009, and the addiction counselling services recorded 
approximately 1,500 prisoner contacts per month. The report 
notes the benefi t of the multidisciplinary approach to the care 
of drug-using prisoners in Mountjoy prison, which aims for a 
personalised therapeutic relationship.
The IPS offers a range of care and rehabilitation services to 
inmates, including those with drug and alcohol problems. 
These services include education, vocational training, and 
psychological and spiritual services, which aim to improve 
re-integration into the community. The IPS works through 
partnership with voluntary and statutory services to enable 
prisoners at risk of homelessness to access appropriate 
accommodation on release.
In a section on prison in-reach services (p. 40), the report states:
A consultant-led Infectious Disease Service has been 
contracted from St. James Hospital to provide treatment 
to prisoners who suffer from infectious diseases, including 
Hep C and HIV. The development of this service has 
demonstrably decreased the number of prisoners 
transferred to St. James Hospital Guide Clinics for screening 
and treatment. It has also been effective in increasing 
compliance with complicated drug regimes and improving 
patient outcomes. The IPS in collaboration with St. James’s 
Hospital are fi nalising arrangements to introduce a Hepatitis 
C Virus treatment service to selected Dublin prisons.
According to the report, 760 people were serving sentences 
for drug offences on 4 December 2009, an increase of 34% on 
the 2008 fi gure of 567. The IPS continued to roll-out various 
security measures introduced in 2008, and has continued to 
test technology for the inhibition of mobile phone signals 
within prisons. 
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The Poisons Information Centre, located in Beaumont Hospital, 
provides a service to doctors and healthcare professionals 
throughout Ireland in the diagnosis and management of poisonings.
The Centre’s annual report3 outlines the number and type of 
enquiries handled in 2009:
The Centre received 9,838 calls in the year: 9,647 • 
(98.1%) concerned cases of poisoning in humans, 89 
(0.9%) concerned poisoning in animals, and 102 (1%) 
were non-emergency requests for information.
Of the 9,838 enquiries, 5,044 (52.3%) were in relation • 
to children under 10 years of age, the majority relating 
to the 1–4-year age group.
Of the human poisoning incidents, 90.8% occurred in • 
a domestic setting; 59.4% were reported as accidental; 
23.2% were suspected to be intentional, or the result 
of recreational abuse; 11.1% were therapeutic errors; 
and 6.3% were of unknown intent.
As in other years, the largest number of enquiries • 
made to the Centre concerned paracetamol, followed 
by ibuprofen, codeine and diazepam.
The most common household products involved in • 
poisoning were laundry products, and the majority of 
these cases were in children under 10 years of age.
In 2009 the Centre saw an increase in the incidence of 
poisoning with alcohol-based hand-gel products. In the past, 
this type of poisoning was seen mainly in hospitals, but an 
increasing number of enquiries in 2009 related to children 
in the home. The report suggests the increase in children’s 
exposure to hand gels is due to their increased availability in 
the home and improper storage. 
Europe 2020: a strategy for smart, sustainable and 
inclusive growth
On 17 June 2010 the European Council adopted Europe 
2020: A strategy for smart, sustainable and inclusive growth 
(EUCO 13/10),4 the EU’s strategic framework for sustainable 
and job-creating growth over the next 10 years. 
By setting targets in relation to employment, research and 
development, greenhouse gas emissions and education, 
the strategy aims to promote social inclusion and remove at 
least 20 million people from the risk of poverty and exclusion 
by 2020. The European Commission has designed seven 
‘fl agship initiatives’ to ‘catalyse progress’ towards the fi ve 
strategic targets, including a ‘European platform against 
poverty’ which has particular relevance to the social inclusion 
target. The aim of this initiative is to ensure economic, social 
and territorial cohesion by raising awareness and recognising 
the fundamental rights of people experiencing poverty and 
social exclusion, thereby enabling them to live in dignity and 
take an active part in society. 
At EU level, the Commission will work to: 
transform the open method of co-ordination on • 
social exclusion and social protection into a platform 
for co-operation, peer review and exchange of 
good practice, and into an instrument to foster 
commitment by public and private players to reduce 
social exclusion, and take concrete action, including 
through targeted support from the structural funds, 
notably the European Social Fund (ESF); 
design and implement programmes to promote • 
social innovation for the most vulnerable, in particular 
by providing innovative education, training, and 
employment opportunities for deprived communities, 
to fi ght discrimination, and to develop a new agenda 
for migrants' integration to enable them to develop 
their potential; 
undertake an assessment of the adequacy and • 
sustainability of social protection and pension 
systems, and identify ways to ensure better access to 
health care systems. 
At national level, member states will need to: 
promote shared collective and individual • 
responsibility in combating poverty and social 
exclusion; 
defi ne and implement measures addressing the • 
specifi c circumstances of groups at particular 
risk (such as one-parent families, elderly women, 
minorities, Roma, people with a disability and the 
homeless); 
fully deploy their social security and pension systems • 
to ensure adequate income support and access to 
health care. 
(Contributors: Suzi Lyons, Jean Long, Simone Walsh and Brigid Pike)
Irish College of General Practitioners (2010) General 1. 
clinical audit fi ndings for Methadone Treatment Protocol. 
Methadone Treatment Protocol Newsletter, (2): 2. Available 
at www.icgp.ie/go/courses/substance_misuse
Irish Prison Service (2010) 2. Irish Prison Service annual 
report. Longford. Irish Prison Service. Available at www.
drugsandalcohol.ie/13615
Poisons Information Centre of Ireland (2010) 3. Annual report 
2009. Dublin: Poisons Information Centre. Available at 
www.poisons.ie/downloads/Annual_Report_2009.pdf
European Council ‘Conclusions on a New Strategy for 4. 
Jobs and Growth’. 17 June 2010. EUCO 13/10; European 
Commission ‘Europe 2020: A strategy for smart, sustainable 
and inclusive growth’. 3 March 2010. COM (2010) 2020. 
Correction: The article on p. 9 of Drugnet 
Ireland Issue 34 should have been titled 
'Guidebook on case management in homeless 
services'. The authors of the guidebook are the 
Homeless Agency Partnership and Progression 
Routes Initiative.
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The Economic and Social Research Institute (ESRI) manages 
the Hospital In-Patient Enquiry (HIPE) scheme. This is a 
computerised health information system designed to collect 
clinical and administrative data on discharges from over 60 
acute hospitals in Ireland. 
This article reports on an analysis of HIPE data on discharges, 
including deaths in hospital, of cases with an alcohol-related 
diagnosis in the years 2005–2008, in order to assess the burden 
of alcohol-related morbidity on Irish hospitals. It is important 
to note that, because the HIPE scheme does not record 
attendances at emergency departments, using HIPE data to 
assess the impact of alcohol use on acute hospital services can 
lead to an under-estimation of the true extent of the burden.
Number of alcohol-related discharges
Between 2005 and 2008 the number of alcohol-related 
discharges increased by 22% (Table 1). Changes in the 
classifi cation of alcohol-related diagnoses introduced in the 
tenth version of the International Classifi cation of Diseases 
– ICD-10, may explain the low number of discharges in 
2005. Males accounted for 74% and females for 26% of 
all discharges. In 2008 the average length of stay was nine 
days and alcohol-related discharges accounted for 3.6% 
(161,016) of all bed days. According to the Health Service 
Executive (HSE), the average cost per bed day in 2008 
was €889.1 We can therefore deduce that alcohol-related 
discharges cost €143,143,224 in 2008.
Table 1 Number and length of stay of alcohol-related
 discharges, 2005–2008 (N=68,565)
2005 2006 2007 2008
Number of 
discharges 15,088 17,053 18,024 18,400
Male 10,971 12,629 13,344 13,579
Female 4117 4424 4680 4821
Average length 
of stay (days) 7.86 8.11 8.04 8.75
% of all bed days 2.9 3.2 3.3 3.6
The burden of alcohol-related morbidity 
on hospital services
Discharges by age
The mean age of discharges was 48 years, and the median 
was 49 years. There was little difference in the age profi le of 
males and females, although male discharges tended to be 
older, with 51% aged 50 years or over, compared to 43% 
of women (Figure 1). One explanation for this may be that 
health complications arising from alcohol tend to manifest 
themselves earlier in the drinking careers of women than in 
men. Alternatively, these trends may be attributable to the 
fact that middle-aged and older women in Ireland drink less 
than men and are also more likely to abstain from alcohol 
altogether.2 Those aged under 18 accounted for 3% (2,083) 
of all discharges. Males accounted for 55% and females for 
45% of discharges aged under 18.
Discharges by diagnosis
Alcohol-related discharges were categorised according to 
diagnosis into one of the following groups: acute conditions, 
chronic diseases and other chronic conditions (Table 2 
overleaf). Twenty-seven discharges with a diagnosis relating 
to fetal alcohol syndrome are not presented in this analysis.
Figure 1  Percentage of alcohol-related hospital
 discharges by gender and age, 2005–2008
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For the purposes of this analysis, cases with both an acute and 
a chronic diagnosis were recorded in the chronic category, and 
cases with both a chronic disease and a chronic condition were 
recorded in the chronic disease category. Acute conditions 
accounted for 18%, chronic diseases for 21% and other 
chronic conditions for 61% of alcohol-related discharges in 
2008 (Figure 2).
Figure 2  Number of alcohol-related discharges by   
 year and diagnosis, 2005–2008 (N=68,538)
2000
4000
6000
8000
10000
12000
0
Acute conditions
Chronic diseases
200820072006
3983 3650 3637 3319
2955 3299 3629 3827
8142 10096 10754 11247
2005
Chronic-other
N
um
be
r
10
Acute conditions were more prevalent among younger 
people, while chronic diseases and other chronic conditions 
were more common among older age groups (Figure 
3). The numbers admitted with chronic diseases or other 
chronic conditions increased steadily with age and peaked 
in the 50–59-year age group; the numbers of discharges 
for both types of condition decreased steadily among those 
aged 60 years or over. Acute conditions accounted for 59% 
of discharges aged under 30. However, it is somewhat 
worrying that in the four years 2005–2008 there were 
4,129 discharges aged under 30 with chronic conditions or 
diseases, given that these conditions usually develop after a 
number of years of harmful drinking and are normally seen 
in much older people. 
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Table 2   Classifi cation of alcohol-related discharges by diagnosis
Acute conditions Chronic diseases Other chronic conditions
ICD code Description ICD code Description ICD code Description
F10.0 Acute intoxication E24.4
Alcohol-induced pseudo-
Cushing’s syndrome
F10.1 Harmful use
T51.0 Ethanol G31.2
Degeneration of nervous 
system due to alcohol F10.2 Dependence syndrome
T51.1 Methanol G62.1 Alcoholic polyneuropathy F10.3 Withdrawal state
T51.2 2-Propanol G72.1 Alcoholic myopathy F10.4
Withdrawal state with 
delirium
T51.3 Fusel oil I42.6
Alcoholic 
cardiomyopathy
F10.5 Psychotic disorder
T51.8 Other alcohols K29.2 Alcoholic gastritis F10.6 Amnesic syndrome
T51.9 Alcohol unspecifi ed K70.0 Alcoholic fatty liver F10.7
Residual and late onset 
psychotic disorder
X45
Accidental alcohol 
poisoning
K70.1 Alcoholic hepatitis F10.8
Other mental and 
behavioural disorders
X65
Intentional alcohol 
poisoning
K70.2
Alcoholic fi brosis and 
sclerosis of liver
F10.9
Unspecifi ed mental and 
behavioural disorder
Y15
Alcohol poisoning – 
undetermined intent
K70.3 Alcoholic cirrhosis of liver Z50.2* Alcohol rehabilitation
R78.0
Finding of alcohol in 
blood
K70.4 Alcoholic hepatic failure Z71.4*
Alcohol abuse counselling 
and surveillance
Y90.0 – Y90.9
Evidence of alcohol 
involvement determined 
by blood alcohol level
K70.9
Alcoholic liver disease, 
unspecifi ed
Z72.1*
Problems related to 
lifestyle – alcohol
Y91.0 – Y91.9
Evidence of alcohol 
involvement determined 
by level of intoxication
K86.0
Alcohol-induced chronic 
pancreatitis
Z86.41*
Personal history of 
alcohol use disorder
*These conditions indicate the presence of an underlying alcohol disorder
The burden of alcohol-related morbidity on hospital services (continued)
Alcoholic liver disease accounted for three-quarters of all 
alcohol-related chronic diseases (Table 3). Alcoholic gastritis 
and alcohol-induced chronic pancreatitis each accounted 
for 9% of chronic diseases. Between 2005 and 2008, 71 
discharges had a liver transplant during their hospital stay.
Table 3 Alcohol-related discharges by disease type,
 2005–2008 (N=13,710)
Number %
Alcoholic liver disease 10349 75.5
Alcoholic gastritis 1295 9.4
Alcohol-induced chronic pancreatitis 1198 8.7
Alcoholic cardiomyopathy 483 3.5
Degeneration of nervous system due 
to alcohol 272 2.0
Alcoholic myopathy 58 0.4
Alcoholic polyneuropathy 55 0.4
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The burden of alcohol-related morbidity on hospital services (continued)
Deaths in hospital of cases with an alcohol-related 
diagnosis
In the period 2005–2008, 1,899 (2.8%) cases died while still 
in hospital; 1,001 (53%) had an alcohol-related disease, 813 
(43%) had a chronic condition and 85 (4%) had an acute 
condition. Males accounted for 72% of deaths (Figure 4). 
Over half (52%) of deaths occurred among those aged 
50–70 years. Male deaths peaked in the 60–69-year age 
group and female deaths peaked in the 50–59-year age 
group (Figure 5).
Figure 3  Percentage of alcohol-related discharges by  
 age and diagnosis, 2005–2008
Figure 5  Number of hospital deaths with an alcohol-  
 related diagnosis by age and gender,   
 2005–2008 (N=1,899)
Figure 4  Number of hospital deaths with an alcohol
 related diagnosis by year and gender,
 2005–2008 (N=1,899)
Those aged under 65 accounted for 61% (1,156) of deaths, 
highlighting the link between alcohol-related conditions and 
premature mortality. As these people were of working age, 
these deaths represent a considerable economic loss to the 
country and contribute to the wider, intangible human costs 
associated with premature mortality due to alcohol. 
Discharges with additional mental health, drug 
or trauma diagnoses
There is a close relationship between alcohol problems and 
mental health. People with mental health problems are at 
increased risk of alcohol problems, and vice versa. One in 
ten male and one in fi ve female cases discharged in the 
four-year period had a mental health diagnosis in addition 
to an alcohol-related diagnosis (Table 4). Eleven per cent of 
discharges had an additional drug-related diagnosis, and half 
of these were aged 15–34 years. Female discharges (18%) 
were twice as likely as males (9%) to have a drug-related 
diagnosis. A large number of the female cases were related to 
intentional poisoning by analgesics or psychotropic agents in 
conjunction with alcohol. 
Acute consequences of alcohol use such as road traffi c 
accidents and assaults were experienced primarily by males, 
and three-fi fths occurred among those aged 15–34 years. 
One in ten discharges had experienced a fall, with one in 
fi ve falls occurring among those aged 65 or over. Alcohol 
problems among the elderly can be hard to detect and often 
go undiagnosed. The clinical presentation of harmful use 
of alcohol in elderly people may differ from that in younger 
people, with elderly people more likely to present with 
non-specifi c complaints, including falls, which may mask the 
underlying problem alcohol use. 
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Additional 
diagnoses 
Male Female
Age group
15–34 35–49 50–64 65+
n (%) n (%) n (%) % % % %
Mental health 8468 (12.4) 3580 (9.7) 4888 (19.8) 23.0 37.4 28.5 11.2
Drug use 7808 (11.4) 4537 (9.0) 3271 (18.1) 51.3 35.0 12.0 1.7
Fall 6681 (9.7) 4997 (9.9) 1684 (9.3) 22.5 24.1 31.1 22.3
Road traffi c 
accident
1051 (1.5) 907 (1.8) 144 (0.8)
61.4 21.6 12.5 4.5
Assault 1446 (2.1) 1267 (2.5) 179 (1.0) 61.8 28.6 8.1 1.5
Table 4   Discharges with additional mental health, drug or trauma diagnoses by age and gender 2005–2008
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Conclusion
These results indicate that alcohol-related morbidity is a 
considerable burden on Irish hospitals, with alcohol-related 
discharges accounting for 161,016 of all bed days in 2008 
at a cost of €143,143,224. The data presented here do 
not include emergency department presentations; we can 
therefore conclude that the actual burden of alcohol on 
acute Irish hospitals is substantially higher. 
(Deirdre Mongan)
1. HSE National Casemix Programme (2010) Letter dated 17 
February in response to Parliamentary Question [5857/10] 
put to the Minister for Health and Children by Caoimhghín 
Ó Caoláin TD. Dáil Éireann, 4 February 2010. Accessed 17 
August 2010 at www.hse.ie/eng/about/PersonalPQ
2. Morgan K, McGee H, Dicker P, Brugha R, Ward M, Shelley 
E et al. (2009) SLÁN 2007: survey of lifestyle, attitudes and 
nutrition in Ireland. Alcohol use in Ireland: a profi le of drinking 
patterns and alcohol-related harm from SLÁN 2007. Dublin: 
Department of Health and Children.
Sponsorship of sports events by the alcohol industry
There is a link between alcohol marketing and consumption. 
According to a WHO report, ‘in markets where alcohol is 
more widely advertised young people are more likely to 
continue to increase their drinking as they move into their 
mid-twenties, whereas drinking declines at an earlier age 
among those who are less exposed.’1 Sports events are 
widely sponsored by alcohol brands. Sports sponsorship by 
the alcohol industry provides an opportunity to build the 
alcohol brand into the name of the event through mention 
in sports commentaries, signage on clothing and sports 
grounds, and products retailed to fans. 
The Department of Health and Children established a 
working group in 2008 to deliver on the commitment in the 
programme for government to discuss the question of the 
sponsorship of sporting events by the alcohol industry with a 
view to phasing it out.2 The group’s terms of reference were:
To facilitate engagement among stakeholders, • 
including representatives from the main sporting 
organisations in Ireland and the alcohol industry 
regarding this issue
To establish the extent of the existing sponsorship of • 
sporting events by the alcohol industry and the terms 
and lengths of existing contracts
To report to the Minister for Health and Children by • 
30 September 2009.
Conclusions of the working group
The working group accepted that sport has many benefi ts 
and contributes to Irish society, while also recognising that 
alcohol is responsible for many harms in Ireland. While all 
members were willing to play their part in reducing this 
harm, views diverged on how this might be achieved. A 
population health approach seeking to reduce overall alcohol 
consumption was favoured by some, while others were 
in favour of focusing on specifi c at-risk groups and on the 
drinking patterns of people who use alcohol harmfully.
It was not possible to establish the full fi nancial extent of 
the existing sponsorships of sporting events by the alcohol 
industry or the terms and length of these contracts. However, 
the fi nancial contribution to sport in Ireland by the industry 
is very signifi cant, with two of the largest national sporting 
bodies (FAI and IRFU) maintaining that their organisations 
could not exist without the support currently provided by 
the alcohol industry.
One view presented to the working group argued for the 
elimination of alcohol sponsorship of sport to protect the health 
of young people in particular. The opposing view was that there 
are huge economic, social and health benefi ts accruing from 
sport and that the support provided by the alcohol industry 
was integral to the survival of mainstream sport.
The working group was not charged with fi nding a means of 
reconciling these two opposing views. It is now a matter for 
the Minister for Health and Children to consider the fi ndings 
of this report and to use them to inform any decisions that 
may be made in relation to sports sponsorship by the alcohol 
industry in Ireland. 
(Deirdre Mongan) 
WHO Regional Offi ce for Europe (2009) 1. Evidence for 
the effectiveness and cost-effectiveness of interventions to 
reduce alcohol-related harm. Copenhagen: World Health 
Organization. p. 70.
Department of Health and Children (2010) 2. Report of 
the working group on sports sponsorship by the alcohol 
industry. Dublin: Department of Health and Children. 
Available at www.drugsandalcohol.ie/13322
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‘What’s the point?’ A conference on 
understanding suicide and supporting life
The aim of this conference was to bring together various 
professionals in suicidology and people who have had 
a direct encounter with suicide, themselves or through 
friends or relatives, in order to review the impact of suicide 
on society, to refl ect on current policy and research in this 
area, and to discuss what helps to prevent suicide. Held in 
Dublin City University’s Helix theatre on 18 June 2010, the 
conference was organised by the DCU School of Nursing, 
Shine (a part-voluntary organisation supporting people with 
mental illness and their families) and St Vincent’s Hospital, 
Fairview. 
The panel and audience included representatives of the 
three hosting organisations and of other public, private, 
voluntary and part-voluntary bodies. There were speakers 
and guests from the National Offi ce of Suicide Prevention 
(NoSP), the Royal College of Surgeons, the Irish Association 
of Suicidology, the National Service Users Executive (NSUE), 
Bodywhys (the Eating Disorder Association of Ireland), 
Mental Health Ireland, GROW, Headline (the national media-
monitoring programme for mental health and suicide), the 
Health Research Board, and other organisations.
Mr Geoff Day, CEO of NoSP, presented alarming WHO 
statistics showing that one suicide occurs globally every 
minute, and one suicide attempt every three seconds.1 In 
Ireland, the highest rate of suicide is among males aged 
between 20 and 24 years; the highest rate for females is 
among those aged between 50 and 54 years.2 Among the 
multiple risk factors for suicide are mental illness; having 
made a previous suicide attempt; substance misuse; physical 
illness; personality traits; being unemployed; socio-economic 
deprivation; unplanned pregnancy; and abortion. Protective 
factors include effi cient coping skills; seeing reasons for 
living; physical health; good family communication; 
supportive schools; good social support; religious affi liation; 
A Vision for Change, the blueprint for Irish mental health 
policy,1 recommends that the mental health services adopt 
a recovery perspective. It broadly defi nes the principle of 
recovery as the belief that people with mental illness can 
recover their self-esteem and regain control of their lives 
despite their illness. However, at present there is no clearly 
laid-out theory of recovery to guide daily clinical practice.2
In February 2010 the Health Research Board (HRB) published 
the research report Reconnecting with life: personal experiences 
of recovering from mental health problems in Ireland.3 Dr Tony 
Bates, the founding director of Headstrong,4 referred to 
this publication as ‘the most important report to have been 
published since Vision, because it brings clarity to an issue that 
has been poorly understood. Without a shared understanding 
and belief in recovery, our services will remain stagnant, 
regardless of how many new resources are provided’.5
employment; and access to quality health treatment. 
Suicidal states and recovery from them constitute a unique 
interaction of individual existential, emotional, cognitive, 
behavioural, physical, family, social, and economic factors. 
While there is no ‘one-size-fi ts-all’ strategy for preventing 
suicide, the approach taken by professionals and policy-
makers can infl uence how a person deals with suicidal 
feelings. Mann and colleagues3 found that factors associated 
with reduction of suicide rates were GP education on 
suicide; development of coping and problem-solving skills; 
education of the community; and regulation of the quantity 
of medication such as paracetamol sold without prescription. 
An Irish study4 developed the theory that, among young 
Irish males, transcending suicidality meant changing 
orientation from death towards life, which required an 
inner struggle towards accepting oneself as worthy of life. 
Professionals who acknowledged such struggle and worked 
together with clients to overcome their fears and concerns 
were perceived as the most helpful. 
The conference highlighted that the circumstances of each 
individual case are complex and multifactorial. Being wealthy 
and healthy does not guarantee protection from suicidal 
feelings at any stage of one’s life. Whereas a lot of data on 
suicide are published nationally and internationally, there 
is a lack of research on understanding individual contexts 
and recovery from suicidal states. A deeper understanding 
of these aspects can help us to develop better suicide 
prevention strategies. For more information about the 
conference please contact shanola@svhf.ie or kartalova@hrb.ie 
(Yulia Kartalova-O’Doherty)
See www.who.int/mental_health/prevention/en1. 
National Offi ce of Suicide Prevention (2009) 2. 
Annual report 2008. Dublin: HSE. Available at www.
drugsandalcohol.ie/12494 
Mann J, Apter A, Bertolote J, Beautrais A, Currier D, Haas 3. 
A et al. (2005) Suicide prevention strategies: a systematic 
review. Journal of the American Medical Association, 294 
(16): 2064–2074. Available at http://jama.ama-assn.org/
cgi/cpmtemt/full/294/16/2064
Gordon E (2010) 4. Re-vitalizing worthiness: a theory of 
transcending suicidality among young men. PhD thesis, 
Dublin City University. Retrieved 15 July 2010 from 
http://doras.dcu.ie/15083
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The aim of the HRB study was to develop a coherent 
theory of recovery from mental health problems 
from the point of view of those recovering. This was 
the fi rst classic grounded theory (GT) study of recovery in 
Ireland carried out from a service-user perspective. Classic 
GT seeks to identify the main concern of the population 
under study.6 Understanding the main concern helps 
service providers to readjust their practices to better 
meet the needs of service users. The study was based on 
individual interviews with 32 self-nominated volunteers 
who had experienced mental health problems more than 
once over a period of two years or more, and who now 
considered that their mental health had improved. 
An analysis of the interviews identifi ed participants’ main 
concern as striving to reconnect with life. The dynamic 
and non-linear process of reconnecting with life had 
three interactive dimensions: 1) reconnecting with self, 
i.e. accepting oneself as a worthy individual capable 
of positive change; 2) reconnecting self with others, 
i.e. experiencing empathic, accepting, and validating 
interaction with others; and 3) reconnecting with self, 
others and time, i.e. getting a glimpse of a positive 
future, coming to terms with the past, and planning and 
executing one’s present. The process involved exploring, 
acknowledging and developing personal strengths and 
capabilities through trial and error.
As the study fi ndings show, some isolated elements of 
recovery-oriented care already exist in Irish mental health 
services, at least in community mental health services. 
Participants complimented individual psychiatrists, 
nurses, psychotherapists and other professionals for 
their understanding, empathy, sense of humour, 
encouragement and listening skills which facilitated their 
reconnection with self, others and time. Educational and 
occupational activities provided by day centres were also 
reported by participants as facilitating their reconnection 
with life. Such qualities and activities need to be 
supported and enhanced, and used as positive examples 
of recovery-oriented care. 
This study also provided qualitative evidence that 
depersonalised, paternalistic and pessimistic attitudes 
and behaviours, which can slow down reconnection with 
life, generally prevail over a person-centred, empathic 
and accepting approach within the Irish mental health 
services. Recovery-oriented mental health care requires 
a paradigm shift towards refocusing on the life goals of 
those recovering, and the vital importance of service 
users' input into the planning and delivery of care. Service 
users should be encouraged to talk at length, narrate their 
story, voice their concerns and aspirations, and participate 
in a dialogue with service providers. 
It is hoped that the study will encourage creative 
innovation in mental health practice and research, 
and will not only improve the quality of care, but also 
contribute to the morale and job satisfaction of service 
providers. The underlying processes and tasks of mental 
health recovery identifi ed in this study are highly 
relevant and applicable to any clinical or community 
context. Service users’ preferred individual strategies for 
reconnecting with life can be effectively combined with 
therapies and supports available in the services and in the 
wider community to match specifi c tasks of reconnecting 
with self, others and time. In addition, this study informs 
the Irish public about the possibility of recovery, and the 
important role of community in reconnection with one’s 
life and thus can aid mental health promotion campaigns.
Viewing recovery as a process of gradual reconnection 
with life embraces and synthesises diverse concepts and 
theories of recovery and rehabilitation in a coherent 
theory of mental health recovery.7 The theory thus 
generated is congruent with the WHO defi nition of 
mental health as ‘a state of well-being in which the 
individual realises his or her own abilities, can cope with 
the normal stresses of life, can work productively and 
fruitfully, and is able to make a contribution to his or her 
community’.8 The generated theory, with its concepts of 
self-acceptance, meaningful connection with others, and 
reconnection with time as it changes can be relevant to 
other health areas, such as recovery from addiction or 
physical illness.9 The relevance and applicability of the 
generated theory to other areas of health and well-being 
can be further addressed by reviews of previous fi ndings, 
or further research carried out from the perspectives of 
users of various health services.
Familiarisation with this study is recommended for mental 
health professionals and educators, service users, carers, 
researchers, policymakers and the general public. 
(Yulia Kartalova-O’Doherty)
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Further update on psychoactive 
substances sold in head shops and on line
Legislation
The Criminal Justice (Psychoactive Substances) Act 2010 
(No. 22 of 2010)1 came into operation on Monday 23 
August 2010. The intention of the Act is to prevent the 
misuse of dangerous or otherwise harmful psychoactive 
substances by making it an offence to sell, import, export 
or advertise such psychoactive substances. The Act provides 
powers to the Garda Síochána (police) to investigate such 
offences and to issue prohibition notices. It allows the 
District Court to institute prohibition and closure orders in 
certain circumstances. The Act also amends the Customs and 
Excise (Miscellaneous Provisions) Act 1988. 
Numbers of head shops
A Garda inventory of head shops in Ireland indicated that 
at their peak in early 2010 there were 113 head shops in 
the country, with at least one in every county. On 11 May 
2010 (the date of the government ban on a range of head 
shop products) there were 102 shops, 11 having closed for 
a variety of reasons. On 12 May, the gardaí visited all head 
shops and warehouses and seized all banned products. 
By 13 May there were 34 head shops selling psychoactive 
substances, and in early August the number increased to 
39 shops. Following the introduction of the Criminal Justice 
(Psychoactive Substances) Act 2010, the gardaí visited head 
shops in early September; only 19 were open and none were 
selling psychoactive substances (Garda Síochána, personal 
communication, 2010).
New substances detected ‘post-ban’ 
Several additional psychoactive substances have been 
identifi ed in head shop products by Dr Pierce Kavanagh 
and his laboratory team (at Trinity College and the Drug 
Treatment Centre Board) since the publication of Issues 33 
and 34 of Drugnet Ireland. The team illustrated their results in 
a ‘post-ban’ identifi cation chart,2 reproduced on pages 
16–17. A summary of the substances identifi ed is given below.
Dimethocaine, also known as larocaine, is a local anesthetic 
with stimulant properties that are nearly as potent as 
those of cocaine. However, anecdotal user reports indicate 
no euphoria and only mild stimulating effects. This drug 
may induce a fast and irregular heart beat which could be 
problematic for those who continuously redose. The drug 
has induced respiratory arrest. Dimethocaine was identifi ed 
in the head-shop products Amplifi ed, Mint Mania and Mind 
Melt. The Ana Liffey Drug Project reported that a number 
of clients experienced negative effects of a product called 
Amplifi er (most likely Amplifi ed). The clients reported that 
the drug is available in two forms; a rock which is smoked by 
pipe and a tablet which is broken down to inject. According 
to the users of this drug, it has a stimulant effect and a bad 
come down. Some users reported paranoia or auditory or 
visual hallucinations.. In August 2010 three users, who had 
a previous mental health diagnosis, were admitted to a 
psychiatric hospital following hallucinations and depression.
AM-694 is a drug which acts as a potent and selective 
agonist for the cannabinoid receptor CB1. No public data 
about AM-694 metabolism is known. AM-694 has emerged 
as a designer drug, and in Ireland, it was detected in the 
product Shamrock. Concerns have been raised over the 
possible toxicity of this compound, because of its likely 
metabolism to w-fl uoroalkanoic acids. 
Glaucine is an alkaloid found in several different plant 
species. It has bronchodilator and anti-infl ammatory effects 
and is used as a cough suppressant in some countries. 
Glaucine may induce fatigue or hallucinations (which are 
usually colourful visual images). This substance was detected 
as the active ingredient in the head-shop product Entrophy. 
Phenethylamine (PEA) is a natural monoamine alkaloid and 
a psychoactive drug with stimulant effects. This substance 
was detected in the head-shop products Diablo, Dr 
Feelgood, Entrophy, Nemesis, and Party On.
Metamfepramone also known as dimethylcathinone, 
dimethylpropion, or dimepropion, is a stimulant drug of the 
phenethylamine, amphetamine, and cathinone chemical 
classes. Dimethylcathinone was evaluated as an appetite 
suppressant and for the treatment of hypotension, but was 
never widely marketed. Metamfepramone is used for the 
treatment of the common cold. This substance was detected 
in a product sold in tablet form as BluE.
Synephrine is the main active compound found in the bitter 
orange which is an extract of a plant called Citrus aurantium. 
It is a stimulant that constricts the blood vessels, increases 
metabolic and heart rates. Synephrine has been identifi ed 
in the head shop products Energy, Go-E, Empathy, Bio 
Happiness, Exotic and Molotov
Mitragynine, an opioid agonist, is a stimulant at low 
doses and a painkiller or sedative at higher doses. It can 
cause constipation, weight loss, dependence, psychosis 
and withdrawal symptoms. It is not controlled in Ireland. 
Mitragynine is an active ingredient in the products Kratom 
and Xscape.
Hordenine occurs in a variety of grassy plants and grains, 
and in some species of cactus. It stimulates the release of 
norepinephrine in humans, and also has antibacterial and 
antibiotic properties. There are unsubstantiated claims that 
hordenine helps people lose weight. It was detected in the 
products Go-E and Dr Feelgood.
5-hydroxytryptophan (5-HTP) is a naturally-occurring 
amino acid and a metabolic intermediate in the biosynthesis 
of the neurotransmitters serotonin and melatonin from 
tryptophan. 5-HTP sourced from the seeds of the plant 
Griffonia simplicifolia is sold over the counter in the US and 
Canada as a dietary supplement and as an antidepressant, 
appetite suppressant, and sleep aid. It is marketed in many 
European countries for the treatment of major depression. 
Several double-blind placebo-controlled clinical trials have 
demonstrated the effectiveness of 5-HTP in the treatment 
of depression, though the quality of the studies has been 
disputed. There are no regulated manufacturing standards 
in place for many herbal compounds and some marketed 
supplements have been found to be contaminated with 
toxic metals or other drugs. 5-HTP was detected in the head-
shop product Dr Feelgood.
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L-dopa (levodopa) is a naturally occurring dietary 
supplement and psychoactive drug found in certain kinds 
of food and herbs. It is synthesized from the essential 
amino acid L-tyrosine in humans. L-dopa is the precursor 
to the neurotransmitters dopamine, norepinephrine 
(noradrenaline), and epinephrine (adrenaline). Aside from 
its natural and essential biological role, L-dopa is also used 
in the clinical treatment of Parkinson's disease (PD) and 
dopamine-responsive dystonia (involuntary spasms of the 
limbs). It was detected in the product Raz.
Desoxypipradrol was developed in the 1950s, and has 
been researched for applications such as the treatment 
of narcolepsy (a condition which results in uncontrolled 
sleeping) and attention defi cit hyperactivity disorder 
(ADHD), and facilitation of rapid recovery from anaesthesia; 
for various reasons its development for application in these 
areas was not continued. The hydroxylated derivative, 
pipradrol, was introduced as a clinical drug for the treatment 
of for depression, narcolepsy and cognitive enhancement 
in organic dementia. Desoxypipradrol was detected in the 
head-shop product Whack.
Tests in recent weeks have identifi ed yet more psychoactive 
substances that may be used as recreational drugs. There is 
very little information available about the uses or effects of 
these substances:
3',4'-Methylenedioxy-a-pyrrolidinobutiophenone • 
(MDPBP) is a stimulant compound developed in the 
1960s which has been reported as a novel designer drug. 
Oleamide•  was found in the smoking blends Smoke 
and Skunk alongside the synthetic cannabinoid JWH-
018, which was classifi ed as the active ingredient. 
There is no evidence that oleamide is used specifi cally 
as a recreational drug. 
Octopamine•  and synephrine are the adrenergic 
amines in bitter orange. 
Buphedrone• , also known as a-methylamino-
butyrophenone, is a stimulant of the 
phenethylamine, amphetamine, and cathinone 
chemical classes that was fi rst synthesized in 1928. 
It has similar effects to methcathinone but is several 
times more potent by weight.
The products caffeine and lignocaine were found in 
numerous head shop products. 
Caffeine is a legal psychoactive stimulant and easy to • 
acquire. Caffeine was found in the products Blowout, 
Bliss Bomb, Diablo, Dr Feelgood, Energy, Embrace, 
Extreme Star Dust, Go-E, Koru, Nemesis, NRG Now, 
Pure NRG, Pinkys, Raz, Sno*berry, Star Dust, and 
Party On., 
Lignocaine (or lidocaine) is an anaesthetic drug; it • 
was found in Extreme Star Dust, Pure NRG, Raz, Star 
Dust. 
(Jean Long)
Criminal Justice (Psychoactive Substances) Act 2010 1. 
(No. 22 of 2010). Available at www.attorneygeneral.ie/
eAct/2010/a2210.pdf 
Kavanagh P, Spiers P, O'Brien J, McNamara S, Angelov 2. 
D, Mullan D et al. (2010) Head shop 'legal highs' active 
constituents identifi cation chart (July-August 2010). 
Dublin: Department of Pharmacology, TCD
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Adulterants, bulking agents and 
contaminants in illicit drugs
At the point of purchase, illicit drugs usually contain 
substances in addition to the active ingredient (or named 
drug); these adulterants can have serious, sometimes fatal, 
health consequences. Substances may be added in order to: 
bulk or dilute the drug, • 
complement or enhance the effects of the active • 
ingredient, 
facilitate the administration of the drug. • 
Also, additional substances or contaminants may be created 
through a chemical reaction during processing, or added 
though accidental contamination during storage. 
A systematic review of the published evidence of drug 
adulterants found in multiple samples of illicit drugs was 
published by the Centre for Public Health (UK) in April 
2010.1 The review included only articles in English. The 
evidence suggests that some adulterants and bulking agents 
are not dangerous. Various types of sugars are used as 
bulking agents in most illicit drugs. An adapted version of 
the authors’ summary of the evidence of adulterants, other 
than sugars, found in heroin, cocaine, methamphetamine, 
ecstasy and cannabis is presented in Table 1. These 
substances are generally added to the drugs during 
processing and can cause health problems.
The fi ndings in the international literature are consistent 
with fi ndings in Ireland. In recent years, the Forensic Science 
Laboratory in Ireland has reported the presence of caffeine, 
paracetamol and levamisole in heroin samples to the Early 
Warning sub-committee of the National Advisory Committee 
on Drugs (NACD). Phenactin, lignocaine and levamisole 
were reported in cocaine, and glass beads were reported 
in cannabis; the latter practice occurred for a short period 
during 2007 and is no longer an issue. 
According to this review, a number of bacterial contaminants 
have been reported in illicit drugs. The negative effects were 
usually experienced by injecting drug users. The bacteria 
identifi ed were: Bacillus anthracis, Bacillus cereus, Clostridium 
botulinum, Clostridium novyi, Clostridium sordellii and 
bacteria causing necrotising fasciitis. Bacterial contaminants 
identifi ed in Ireland were Clostridium botulinum (in 2005) and 
Clostridium novyi (in 2002). 
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Adulterants in illicit drugs (continued)
Table 1 Adulterant by drug type
Heroin
Adulterant Licit use Possible reason for presence Public health risks and health 
consequences 
Phenobarbital Sedative Facilitates smoking of heroin Overdose in injectors, death
Quinine Anti-malarial 
medication
As a diluent 
Has bitter taste similar to heroin 
Mimics respiratory rush felt by 
heroin injectors
Gastric disturbances, blood clotting, 
low blood pressure, blindness, 
renal failure, CNS over-stimulation, 
overdose (headache, hearing loss, 
tinnitus), death
Clenbuterol Decongestant and 
bronchodilator
Unknown 
May be accidental
Dilated pupils, agitation, 
cardiovascular events, 
neuromuscular syndrome, overdose 
and poisoning at high dose
Scopolamine Anticholinergic Increases retention 
when volatised
Drowsiness at low dose, euphoria at 
high dose, poisoning
Lead Soft metal May be a residue of 
manufacturing process
Headache, dizziness, nausea 
and vomiting, abdominal cramps, 
muscle weakness, anaemia, seizures, 
coma, CNS damage, renal damage, 
poisoning
Caffeine Psychoactive 
stimulant
Legal and easy to acquire 
Vaporises heroin at lower 
temperature and makes smoking it 
more effi cient 
Anxiety, sleep disturbance, mood 
disturbance, addictive, risk factor for 
a range of health conditions
Procaine Local anaesthetic Facilitates smoking and reduces pain 
at the injection site 
Nausea and vomiting, dizziness, 
tremors, anxiety, convulsions, CNS 
problems, poisoning at high doses
Paracetamol Pain medication Same function, painkiller, same 
taste, and similar melting point 
May be used to disguise poor 
quality heroin
Gastro-intestinal effects, liver 
damage, death, risk of toxicity 
at high doses
Strychnine Pesticide Not easy to detect Abnormal posture caused by severe 
muscle rigidity, muscle spasm, 
death, poisoning at medium doses
Cocaine
Adulterant Licit use Possible reason for presence Health consequences 
Lidocaine Local anaesthetic Similar but stronger anesthetic 
than cocaine
Gives the impression of high purity
Nausea, vomiting, dizziness, 
tremors, convulsions, adverse 
cardiac events, CNS problems, 
increases toxicity of cocaine
Hydroxyzine Sedative 
Anxiolytic 
Antihistamine
Unknown Headaches, dizziness, tinnitus, 
drowsiness, gastrointestinal effects, 
loss of consciousness, CNS 
problems, overdose
Phenactin Pain medication 
Banned in many 
countries
Analgesic neuropathy, haemolytic 
anaemia, methheamoglibinanaemia, 
bladder cancer, renal cancer, renal 
failure
Levamisole Medication used to 
dispel worms from 
the intestine
Unknown, 
may give a more intense high
Fever, agranulocytosis, toxic
Caffeine Psychoactive 
stimulant
Legal and easy to acquire Anxiety, sleep disturbance, mood 
disturbance, addictive, risk factor for 
a range of health conditions
Procaine Local anaesthetic Facilitates smoking and reduces pain 
at the injection site
Nausea, vomiting, dizziness, 
tremors, anxiety, convulsions, CNS 
problems, poisoning at high doses
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Adulterants in illicit drugs (continued)
Adulterant Licit use Possible reason for presence Health consequences 
Strychnine Pesticide Not easy to detect Abnormal posture caused by 
severe muscle rigidity, muscle 
spasm, poisoning at medium 
doses, death 
Methamphetamine
Adulterant Licit use Possible reason for presence Health consequences 
Methylsulfonyl- methamine 
(MSM)
Dietary 
supplement
Creates the impression of high-
quality methamphetamine
None known
Caffeine Psychoactive 
stimulant
Legal and easy to acquire Anxiety, sleep disturbance, 
mood disturbance, addictive, 
risk factor for a range of health 
conditions
Lead Soft metal May be a residue of 
manufacturing process
Headaches, dizziness, nausea 
and vomiting, abdominal 
cramps, muscle weakness, 
anaemia, seizures, coma, 
CNS damage, renal damage, 
poisoning
Ecstasy
Adulterant Licit use Possible reason for presence Health consequences 
Dextromethorphan Cough 
suppressant
Euphoria similar to ecstasy when 
taken at high doses
Tachycardia, lethargy, ataxia, 
nystagmus, heatstroke
Amphetamine and/or 
Methamphetamine
Stimulant drug Similar properties to ecstasy, 
Often sold as or in combination 
with ecstasy
Anxiety, sleep disturbance, 
mood disturbance, addictive
Paramethoxymethamphetamine 
and/or 
Paramethoxyamphetamine
Psychoactive 
drug
Added to enhance stimulant 
properties
Fatal at high dosage
Caffeine Psychoactive 
stimulant
Legal and easy to acquire Anxiety, sleep disturbance, 
mood disturbance, addictive, 
risk factor for a range of health 
conditions
Cannabis
Adulterant Licit use Possible reason for presence Health consequences 
Lead Soft metal Increases weight Headache, dizziness, nausea 
and vomiting, abdominal 
cramps, muscle weakness, 
anaemia, seizures, coma, CNS 
damage, poisoning, renal 
damage, death
Aluminium Soft metal Unknown, but may result from 
impure water supply during 
processing
Exacerbates smoking-related 
diseases
Glass May be to 
increase weight
Inhalation of hot glass fumes 
may lead to: sore mouth, 
mouth ulcers, tight chest, 
persistent cough
Source: Adapted from Cole et al. (2010): Table 1.
(Jean Long)
1. Cole C, Jones L, McVeigh J, Kicman A, Syed Q and Bellis M (2010) Cut: a guide to adulterants, bulking agents 
and other contaminants found in illicit drugs. Liverpool: Liverpool John Moores University. 
Available at www.cph.org.uk/showPublication.aspx?pubid=632
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Pat Carey TD, Minister for Community, Equality and 
Gaeltacht Affairs, launched the new HSE drug awareness 
campaign ‘Legal or illegal highs can cause serious health 
problems – they’re anything but safe’ in July 2010.1 The 
minister welcomed the campaign as an important part of 
the strategy against head shop drugs, alongside the ongoing 
legislative reform. 
Introducing the campaign, Ms Alice O’Flynn, HSE 
assistant national director for social inclusion, said that 
the risk to mental and physical health as a result of taking 
these substances was very real. The campaign aims to 
raise awareness of the ill effects in a series of messages 
highlighting the health risks, such as heart problems, kidney 
failure, impotence, seizures and paranoia. 
Aimed primarily at people aged between 15 and 40 years, 
the campaign messages will be reproduced on posters 
and t-shirts, and in a Z-folded wallet card. They will also 
feature on radio ads, in cinemas, in ’pop-ups’ on Facebook, 
in washrooms in bars and clubs, and at festivals over the 
summer. The campaign was developed in consultation with 
all the key stakeholders, including the target audience. 
There is also an information booklet for parents 
and guardians. The booklet explains what legal highs are 
and the current legal issues, and offers some basic advice 
on how to talk to your child about these drugs and what to 
do if they are using them. It includes information on harm 
reduction and on what to do if someone is having a bad 
reaction to a drug. 
A range of presenters also spoke at the launch. Dr Una 
Geary, consultant in emergency medicine, spoke about 
her experience of treating young people who had taken 
head shop drugs. She spoke about the serious damage and 
harm that she had seen, ranging from cardiac problems 
to psychosis. Dr Eamon Keenan, consultant psychiatrist in 
addiction, spoke about addiction and psychological problems 
such as delusions and depression, and of the effect of the 
proliferation of head shop products on the addition services. 
Other speakers included Tanya and Justin from the Voices 
of Youth organisation and Sinead O’Mahony Carey, HSE. 
The www.drugs.ie website provides an online presence for 
the campaign. Andy Osborne explained how the website 
has been updated to include new information on legal and 
illegal highs and resources for young people and parents/
guardians. The website also has a directory of counselling, 
education, treatment, rehabilitation and other services 
responding to problem drug and alcohol use throughout 
the country. Podcasts, videos of interviews with experts and 
other multimedia resources are also available on the site. The 
drugs helpline number is 1800 459 459.
(Suzi Lyons)
1. Carey P (2010, 7 July) Minister Pat Carey launches 
National Drugs Awareness Campaign. Press release issued 
by Department of Community, Equality and Gaeltacht 
Affairs. Available at www.pobail.ie/en/PressReleases/
htmltext,10421,en.html
HSE awareness campaign on legal and 
illegal highs
Lapse and relapse following inpatient 
treatment of opiate dependence
A paper published in 20101 examined the factors associated 
with lapse and relapse2 in a prospective follow-up study of 
opiate users who had been admitted to an Irish residential 
detoxifi cation facility between June 1995 and December 
1996. Follow-up interviews were conducted by out-reach 
workers between June 1998 and March 1999. 
Of the 109 participants, 99 (91%) reported a relapse. Within 
the fi rst week of discharge, 72 (66%) had lapsed and 64 
(59%) had relapsed. Only 42 (32%) of those recruited had 
completed the full six-week programme.
The study identifi ed several factors independently associated 
with early relapse: being aged 20 to 24, not having a partner 
who used opiates, history of injecting drug use, heroin 
use of between 1.5 and 3 ‘quarters’ per day, and failure to 
complete treatment or enter aftercare.
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Lapse and relapse following inpatient treatment of opiate dependence 
(continued)
This study, based on data collected in the late 1990s, found 
that lapse and relapse occurred very soon after opiate 
detoxifi cation: 80% of participants had lapsed within 
the fi rst month. The study fi ndings are similar to those of 
international studies based on more recent data. The authors 
recommend that clients should be provided with improved 
psychological supports both before and after entering 
residential opiate detoxifi cation. These include encouraging 
clients to remain for the full treatment period, improving 
relapse prevention supports, especially during the fi rst week 
after discharge, and providing prompt access to aftercare. 
(Suzi Lyons)
1. Smyth BP, Barry J, Keenan E and Ducray K (2010) Lapse 
and relapse following inpatient treatment of opiate 
dependence. Irish Medical Journal, 103(6): 176–179. 
Available at www.drugsandalcohol.ie/13405
2. A lapse was defi ned as any misuse of an opiate after 
discharge, and a relapse as a return to a pattern of daily 
opiate use.
Reintegration of prisoners in Ireland
In May 2010 the Irish Penal Reform Trust (IPRT) published 
the report ‘It’s like stepping on a landmine…’: reintegration 
of prisoners in Ireland.1 The IPRT is an independent non-
governmental organisation which campaigns for the rights 
of people in prison and the reform of penal policy. 
The study, conducted between October 2009 and February 
2010, consisted of a literature review, a number of semi-
structured interviews with service providers (in the statutory 
and non-statutory sectors), a questionnaire completed by 
service providers throughout Ireland, and two focus groups 
with ex-prisoners in Dublin. The report lists the aims of the 
study:
to review national and international practice and  ■
policy (including human rights standards) relating to 
reintegration;
to identify barriers to reintegration of ex-prisoners in  ■
Ireland;
to map, as far as possible, available services and identify  ■
possible gaps in service provision; and
to make recommendations for development of future  ■
policy and practice.
The study found that, although ‘signifi cant progress has been 
made in recent years in integrating post-release services… 
by the Irish Prison Service [IPS] and its partners, there 
remains a less than uniform approach to the provision of 
necessary services in individual prisons and access to support 
is dependent on the facility in which the prisoner fi nds 
his- or herself’ (p.3). Service provision also varies between 
different areas of the country. The study also found that the 
unstructured use of Temporary Release (TR), often used to 
alleviate pressure on overcrowded prisons and to make spaces 
available to new prisoners, impacts negatively on preparation 
for release. The study found that prisoners are sometimes 
given no more than a few hours notice before being released, 
and some are released when outside services are unavailable, 
on Friday evenings or at the weekend for example.
The report notes some positive developments in recent 
years, such as the development of a system of Integrated 
Sentence Management (ISM) in some prisons, and wider 
provision of drug counselling services, including those 
provided in Dublin by Merchants’ Quay Ireland. The IPRT 
makes a number of recommendations arising from the 
fi ndings of the study, including the following:
The IPS should provide appropriate access and facilities  ■
for practitioners working with prisoners on drug and 
alcohol addictions, including the provision of facilities 
ensuring confi dentiality and a therapeutic environment 
for service users.
All prisons should provide drug-free landings. ■
The IPS, in partnership with relevant service providers,  ■
should ensure arrangements are made for prisoners to 
continue drug and alcohol addiction treatment upon 
release when required.
The government should make the introduction of  ■
spent convictions legislation a priority in 2010, to assist 
prisoners in entering employment post release.
The authors state that during the research it became clear 
that they would not be able to address many of the issues 
which arose, including the specifi c needs of children and 
young people leaving custody, or of foreign national 
prisoners, and the needs of families who support prisoners 
during custody and upon release. The IPRT plans to follow 
up on these issues in the near future.
(Johnny Connolly)
1. Martynowicz A and Quigley M (2010) ‘It’s like stepping 
on a landmine’; reintegration of prisoners in Ireland. 
Dublin: Irish Penal Reform Trust. Available at 
www.drugsandalcohol.ie/13496
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Drug Treatment Court to continue 
operating
In May 2010, the Minister for Justice and Law Reform, 
Dermot Ahern TD, published a review by his department of 
the Drug Treatment Court (DTC) which has been operating 
in Dublin since 2001.1 
According to the department’s press release:2 ’Participants 
who engage with the programme have reduced rates 
of recidivism and improved health, education and social 
skills, which impact positively on the participants and the 
community. However, the review also confi rmed that the 
DTC, as currently operating, is not dealing with suffi cient 
numbers of participants and programme completion rates 
are very low.’ 
The press release quotes Minister Ahern: ‘Drug treatment 
courts can make an important contribution as a restorative 
justice measure but international studies also indicate they 
need to evolve and develop on an ongoing basis. This review 
stems from my concern about the very low throughput of 
participants in the DTC programme, despite the dedicated 
team attached to the Court and considerable goodwill on 
the part of all the agencies involved. I am pleased therefore 
that the report has identifi ed a number of recommendations 
which should lead to a marked improvement in the 
programme's throughput and effectiveness.’ 
The review sought to ascertain why so few people were 
going through the DTC, how throughput could be increased 
and whether further expansion was desirable given 
poor results thus far. It identifi ed the following costs and 
outcomes:
Average annual justice sector cost for the years • 
2001–2009 was €300,000.
A total of 374 people were referred in the nine-year • 
period, of whom 174 were deemed unsuitable (90% 
of whom were outside the DTC catchment area).
Twenty-nine people have graduated from the • 
programme (14% of 200).
Involvement in the court led to signifi cant reduction • 
in offending.
Estimated weekly cost of DTC per offender in 2008 • 
was €320.
Weekly cost of a prison space in 2008 was • €1,783.
The press release continues: ‘The review identifi es particular 
issues to be addressed in terms of the management and 
operation of the DTC which, when implemented will, it 
concludes, enable the DTC to fulfi l its potential in terms 
of the numbers participating in the programme and 
increasing the numbers who successfully complete it. 
The review recommends that, having implemented the 
recommendations, the DTC should continue its operations 
for a further two years with an interim assessment to 
consider if the improvements are being achieved.’ 
The review identifi ed the following reasons for the low 
number of referrals to the DTC:
Eligibility criteria exclude offenders aged under 18, • 
those from outside the defi ned catchment area, 
and those whose offences involve violence.
Offenders can only be referred to the DTC when • 
they have pleaded guilty and/or have been convicted 
of certain offences where a prison sentence is likely.
Judges/solicitors are unaware of the DTC as • 
an option.
There is a lack of management support • 
and resources.
The press release concludes: ‘The DTC operates on a 
multi-agency basis and all the agencies involved have 
confi rmed their continued commitment to support the 
work of the Court. The Courts Service has agreed that the 
administration of the project will now be led by the Chief 
Clerk of the Dublin Circuit and District Courts, supported 
by a designated Deputy Chief Clerk who will be appointed 
shortly. The review also recommends the establishment 
of an Advisory Committee to oversee the project. This will 
be chaired by the Courts Service and made up of senior 
staff members of the Garda Síochána, the Health Service 
Executive, the Probation Service and the City of Dublin 
Vocational Educational Committee, and will consider the 
entry requirements to the programme, expectations of 
participants and measures of success and how the numbers 
of participants in the programme can be increased quickly. 
The Committee will also look at the questions of research 
into the work and effectiveness of the DTC process and 
examine how third-level institutions might assist the Court in 
this work.’
(Johnny Connolly)
1. Department of Justice, Equality and Law Reform (2010) 
Review of the drug treatment court. Dublin: Stationery 
Offi ce. Available at www.justice.ie
2. Ahern D (2010) Ahern publishes review of Dublin's Drug 
Treatment Court. Press release issued by Department of 
Justice and Law Reform, 24 May 2010. 
Available at www.justice.ie
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Information on drug testing in prisons in 2009 was obtained 
from the Irish Prison Service. These data indicate that more 
than 28,000 voluntary tests were carried out to monitor 
drug use and responses to treatment in 2009. These tests 
included those carried out on some committals (new entries) 
as well as those carried out on existing inmates. It may be 
assumed therefore that some of the positive test results 
relate to drugs or alcohol consumed outside the prison. 
Excluding methadone, between one-tenth and two-
fi fths of those screened tested positive for at least one 
drug. The common metabolites detected indicated use 
of cannabis, benzodiazepines and opiates (Table 1). It is 
not clear whether the numbers of positive cases exclude 
prisoners who were prescribed benzodiazepines; if they 
do not, these fi gures overstate the extent of unregulated 
use of benzodiazepine in prisons. Cocaine, amphetamines 
and alcohol were detected in a small number of tests. The 
profi le of positive opiate and benzodiazepine tests indicated 
moderate use of such drugs among prisoners tested in 
Mountjoy, Wheatfi eld and Portlaoise prisons. The proportion 
of positive tests was very low in St Patrick’s Institution and 
in the Training Unit. It would be useful if the test results of 
prisoners who were tested at committal interview could be 
fully removed from this analysis as this would provide a more 
accurate assessment of drug use in Irish prisons. 
(Jean Long)
Table 1 Number of tests, by prison, and number (%) of positive tests, by prison and by drug type, 2009
Prison
No. of 
tests
Cannabis 
Benzo-
diazepines Methadone Opiates Cocaine 
Amphet-
amines Alcohol 
Number (%)
Mountjoy Male 6102 2661 (44) 2717 (45) 5148 (84) 3519 (58) 46 (0.8) 1 (0.02) 28 (0.5)
Mountjoy 
Medical Unit 4366 679 (16) 664 (15) 2018 (46) 667 (15) 7 (0.2) 3 (0.07) 7 (0.2)
Dóchas Centre 2491 450 (18) 1214 (49) 2045 (82) 557 (22) 53 (2) 4 (0.2) 21 (0.8)
Training Unit 2607 24 (0.9) 15 (0.6) 1 (0.04) 38 (1.5) 0 (0) 1 (0.04) 4 (0.2)
Wheatfi eld 4131 1303 (32) 1229 (30) 3664 (89) 1499 (36) 12 (0.3) 2 (0.04) 16 (0.4)
Cloverhill* 2328 290 (12) 414 (18) 1604 (69) 389 (17) 43 (2) 3 (0.1) 36 (2)
St Patrick's 
Institution 1312 105 (8) 66 (5) 158 (12) 16 (1) 1 (0.1) 0 (0) 6 (0.5)
Castlerea 126 33 (26) 33 (26) 23 (18) 36 (29) 1 (0.8) 1 (0.8) 2 (1.6)
Loughan House 486 157 (32) 88 (18) 4 (0.8) 44 (9) 2 (0.4) 5 (1) 5 (1)
Shelton Abbey 770 150 (19) 55 (7) 3 (0.4) 15 (1.9) 7 (0.9) 1 (0.1) 10 (1.3)
Limerick 695 120 (17) 236 (34) 593 (85) 176 (25) 2 (0.3) 3 (0.4) 4 (0.6)
Cork 165 26 (16) 18 (11) 0 (0) 3 (2) 0 (0) 1 (1) 1 (0.6)
Midlands 2529 400 (16) 551 (22) 2287 (90) 908 (36) 15 (0.6) 3 (0.1) 27 (1)
Portlaoise 107 31 (29) 39 (36) 59 (55) 32 (30) 2 (1.9) 0 (0) 0 (0)
Arbour Hill 27 3 (11) 2 (7) 1 (4) 1 (4) 1 (4) 1 (4) 0 (0)
*Results for Cloverhill exclude all committal cases; those for all other facilities exclude only some committal cases.
Source: Irish Prison Service, unpublished data, 2010 
Drug Tests in Irish prisons
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Figure 1 Time between release from prison and 
death (n=89), NDRDI 1998–2005
Drug-related deaths among recently 
released prisoners
International research has found an increased risk of 
mortality among prisoners within the days and weeks 
following their release from prison.1 Many of these deaths 
are drug-related and the increased mortality risk is thought 
to be caused by the altered tolerance to drugs which an 
individual may develop while in prison.2 A recently published 
paper based on data from the National Drug-Related Deaths 
Index (NDRDI) for the years 1998–2005 examined the 
relationship between date of release from prison and drug-
related death.3 This was the fi rst study of its kind in Ireland.
Profi le of cases examined 
Between 1998 and 2005, 2,442 drug-related deaths 
were recorded on the NDRDI. One hundred and thirty 
of the individuals who died had a documented history of 
imprisonment. Of the 130 individuals, 105 were not in 
prison at the time of death. The analysis presented in this 
article is based on these 105 individuals, of whom:
the majority (93, 88.6%) were male; • 
most (69, 65.7%) were aged between 20 and 29 • 
years (median age 29 years);
the majority (88, 83.8%) were unemployed; • 
21 (20.0%) were living in unstable accommodation, • 
and 10 (9.5%) were homeless;
64 (61.0%) had a history of injecting, and 36 • 
(34.3%) were injecting at the time of death;
11 (10.5%) had a blood-borne viral infection • 
recorded in their history, of whom fi ve were co-
infected with two or more viruses.
Time between release from prison and death
Of the 105 individuals, 89 had a known date of release. Of 
these, nine (10.1%) died on day one or day two, and 16 
(18.0%) died between day three and day seven. Almost half 
(42, 47.2%) of the 89 deaths occurred within the fi rst month 
of release (Figure 1). 
Deaths by poisoning within the fi rst month of release 
Of the 42 deaths within the fi rst month of release, 38 were 
due to poisoning (Table 1), and many of those who died 
were injecting drugs at the time of their death. Of the 14 
deaths involving a single drug, 11 involved an opiate, mainly 
heroin and/or methadone. Of the 24 deaths involving 
polysubstances, 23 involved an opiate (in addition to one or 
more other substances). 
Table 1 Substances involved in deaths by poisoning 
within the fi rst month of release (n=38)
Substance n (%)*
Heroin 19 (50.0)
Methadone 18 (47.4)
Benzodiazepines 11 (28.9)
Antidepressants 6 (15.8)
Stimulants† 7 (18.4)
Other‡ 11 (28.9)
* The sum of percentages in this column exceeds 100% 
as most deaths involved more than one substance.
† Includes cocaine and methamphetamine.
‡ Includes non-benzodiazepine sedatives, unspecifi ed 
opiates, analgesics containing an opiate compound, 
anti-psychotics, non-opiate analgesics, alcohol, 
solvents, cardiac and all other types of medication, 
including over-the-counter products.
The fi ndings of this study are consistent with those of 
international studies in this area. The number of cases 
reported in this study is likely to be underestimated, as 
history of imprisonment is not routinely recorded in the 
NDRDI data sources. The study highlights the need for 
education and awareness among prisoners and their families 
and friends about the risk of overdose in the days and weeks 
following release. Many of these deaths are preventable and 
the fi ndings of the study support the need for an overdose 
prevention strategy.
(Simone Walsh and Suzi Lyons)
1. See, for example, Binswanger I et al. (2007) Release from 
prison – a high risk of death for former inmates. New 
England Journal of Medicine, 356(2): 157–165; Kariminia 
A et al. (2007) Suicide risk among recently released 
prisoners in New South Wales, Australia. Medical Journal 
of Australia, 187(7):387–390. 
2. See, for example, Jones R, Gruer L, Gilchrist G et al. 
(2002) Recent contact with health and social services by 
drug misuers in Glasgow who died of a fatal overdose 
in 1999. Addiction, 97: 1517–1522; Seymour A, Oliver J 
and Black M (2000) Drug-related deaths among recently 
released prisoners in the Strathclyde region of Scotland. 
Journal of Forensic Science, 45(3): 649–654.
3. Lyons S, Walsh S, Lynn E, Long J 2010 Drug-related 
deaths among recently release prisoners in Ireland 1998 
to 2005. International Journal of Prisoner Health, 6(1): 
26–32. Available at www.drugsandalcohol.ie/13332.
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Finglas Addiction Support Team 
launches two reports
Pictured at the launch of the FAST reports: Family support group, manager of FAST, and Finglas LDTF and aftercare workers
The Finglas Addiction Support Team (FAST) was established 
in 2004 and is funded by the Finglas/Cabra Local Drugs 
Task Force (LDTF). It is a holistic service providing support 
to individuals and families affected by drug- and/or 
alcohol-related problems in the greater Finglas area. It 
offers a number of services, including counselling, support 
for cocaine users, aftercare support, family support and 
complementary services.
Pat Carey, TD for Finglas and Minister for Community, 
Equality and Gaeltacht Affairs, recently launched two 
reports for FAST, Services report 20091 and Strategic plan 
2010–2013.2
Services report 2009 highlights the range and volume of 
work undertaken by FAST. In 2009, 412 individuals accessed 
the service.
Of those who accessed cocaine support: 
50% experienced a reduction in mental health • 
problems such as depression and suicidal thoughts, 
and paranoia,
45% stopped using drugs/became drug free.• 
Of those who accessed aftercare:
90% maintained drug free status,• 
70% moved back into mainstream society.• 
Of those who accessed family support:
80% improved the stability of their family unit,• 
95% increased their knowledge of addiction.• 
Strategic plan 2010–2013 details the rationale and road map 
for the service going forward. Key objectives for the coming 
years include:
Consolidate existing services and structures,• 
Promote a community of acceptance in Finglas,• 
Promote genuine person-centred progression routes,• 
Balance the service/programme elements of FAST • 
with community development and volunteerism,
Expand the current premises,• 
Prove the business case for FAST and secure • 
additional funding to mitigate budgetary cuts to 
existing services.
Minister Carey commended Ms Barbara Condon, FAST 
manager, and all the staff on the quality of their work 
and the positive outcomes they had achieved, noting in 
particular the cocaine-specifi c services and the drug and 
alcohol services provided. Mr Carey went on to say ‘in terms 
of alcohol, I am sure all of you here tonight are aware that 
my Department together with the Department of Health 
& Children are jointly developing proposals for a National 
Substance Misuse Strategy that will combine the approaches 
to alcohol and drugs. This is something that I have 
advocated for some time and I look forward to proposals 
going to Government on the matter by the end of the year.’
FAST has recently received funding of 1.5 million Euro 
through the Department of Community, Equality and 
Gaeltacht Affairs and Finglas/Cabra Local Drugs Task Force to 
redevelop their current premises; the work will commence at 
the end of the summer.
(Mairea Nelson)
1. Finglas Addiction Support Team (2010) Services report 
2009. Dublin: Finglas Addiction Support Team Ltd. 
Available at www.drugsandalcohol.ie/13319
2. Russell C (2010) Strategic plan 2010–2013. Dublin: 
Finglas Addiction Support Team Ltd. Available at www.
drugsandalcohol.ie/13320
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National Registry of Deliberate Self Harm 
annual report 2009
The eight annual report from the National Registry of 
Deliberate Self Harm was published in July 2010.1 The 
report contains information relating to every presentation of 
deliberate self-harm to hospital emergency departments in 
2009, giving complete national coverage of hospital-treated 
deliberate self-harm. 
In 2009, there were 11,966 presentations of deliberate 
self-harm, involving 9,493 individuals, to emergency 
departments. The rate of presentations increased from 
200/100,000 of the population in 2008 to 209/100,000 
in 2009, a 5% increase. Repeat presentations accounted 
for more than one in fi ve (21%) of all presentations. The 
biggest rise in the number of presentations was observed in 
men, with an increase of 10% on the 2008 fi gure. This is the 
second successive major increase in such cases, following an 
11% increase in 2008.
For the fi rst time, the report details and maps the incidence 
of male and female deliberate self-harm by HSE local health 
offi ce (LHO) area of residence. This, the authors hope, will 
raise awareness of the problem of deliberate self-harm among 
LHO primary and community care service providers. Limerick 
LHO area had the highest male rate and the second highest 
female rate. Cork North Lee and Louth LHO areas had high 
rates of deliberate self-harm for men only. Four of the eight 
Dublin LHO areas (Dublin North Central, Dublin West, Dublin 
South West and Dublin North West) were associated with 
high rates of deliberate self-harm for both men and women. 
In contrast, the incidence of male and female self-harm was 
low in Dublin South East and Dun Laoghaire. 
Concordant with previous reports, deliberate self-harm was 
largely confi ned to the younger age groups. Almost half 
(45%) of all presentations were among people aged under 
30 years. Among females, those aged 15–19 years were most 
likely to present with deliberate self-harm. The increase in 
male presentations was observed in several age groups. The 
rate among men aged 20–24 years increased by 21%. There 
was an increase in the number of 10–14-year-olds presenting.
Drug overdose was the most common form of deliberate 
self-harm, occurring in 71% of all such episodes reported 
in 2009. Overdose rates were higher among females (78%) 
than among males (64%). On average, at least 31 tablets 
were taken in episodes of drug overdose. The total number 
of tablets taken was known in 74% of cases. Forty-two per 
cent of all drug overdoses involved a minor tranquilliser, 
29% involved paracetamol-containing medicines and 21% 
involved anti-depressants/mood stabilisers. The number of 
deliberate self-harm presentations involving street drugs 
increased by 26% in 2009 (from 461 to 579).
There was evidence of alcohol consumption in 41% of all 
episodes of deliberate self-harm and this was more common 
among men (45%) than women (37%). Alcohol may be one 
of the factors underlying the pattern of presentation by time 
of day and day of week. Presentations peaked in the hours 
around midnight and almost one-third occurred on Sundays 
and Mondays.
Attempted hanging was involved in 608 of all deliberate 
self-harm presentations (7% of men and 3% of women). This 
is the highest number of attempted hangings recorded by 
the Registry, and was 18% higher in 2009 than in 2008. Self-
cutting was used in one in fi ve cases (22%) and signifi cantly 
more often by men (25%) than by women (19%). 
The emergency department was the only treatment setting 
for 44% of all deliberate self-harm patients, that is, they did 
not proceed to further treatment.
The report recommends the following measures to reduce 
the incidence of deliberate self-harm:
Provide increased support for evidence-based • 
prevention and mental health promotion 
programmes. 
Develop and implement initiatives to increase • 
awareness of mental health issues among the 
general public and service providers supporting 
the unemployed or people experiencing fi nancial 
diffi culties.
Develop a system to enable deliberate self-harm data • 
to be linked with suicide mortality data to enhance 
insight into predictors of suicide risk. 
Restrict access to minor tranquillisers as they are • 
the most common type of medication involved in 
intentional acts of drug overdose.
Increase awareness among addiction service • 
professionals and service users of the risk of suicidal 
behaviour related to drug abuse.
Enhance health service capacity at specifi c times and • 
increase awareness of the negative effects of alcohol 
misuse and abuse, such as increased depressive 
feelings and reduced self-control.
Consideration should be given by LHOs to the • 
development of response plans and intervention 
programmes related to suicidal behaviour.
Minimum guidelines for the assessment of deliberate • 
self-harm patients should be implemented by the HSE 
in line with the guidelines of the National Institute for 
Clinical Excellence in the UK.
Provide uniform psychosocial and psychiatric • 
assessment to all self-harm patients, paying particular 
attention to patients using highly lethal methods.
Prioritise national implementation of evidence-based • 
treatments shown to reduce risk of repetition, such 
as cognitive behavioural, dialectical behavioural and 
problem-solving interventions.
(Mairea Nelson)
1. National Registry of Deliberate Self Harm Ireland (2010) 
Annual report 2009. Cork: National Suicide Research 
Foundation. Available at www.drugsandalcohol.ie/13249
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Drugs and prison: improving our understanding
Cited from article by Linda Montanari and Dagmar Hedrich in 
Drugnet Europe No. 71, July–September 2010
A considerable proportion of the prison population in 
Europe is made up of drug law offenders and of drug users 
who have committed drug-related crime to support their 
addiction. Drug using prisoners often suffer from health 
problems (e.g. infectious diseases, mental disorders) and, 
on account of reduced tolerance are at high risk of a fatal 
drug overdose after release. Yet, in many countries, drug 
interventions in the prison setting remain limited.
In this context, the EU drugs action plan (2009–12) sets 
the goal of developing a methodological framework for 
monitoring drug use, drug-related health problems and 
drug service delivery in prisons (1). This work, to be carried 
out by the European Commission, with the support of the 
EMCDDA, will be based on steps already taken in this fi eld 
by the EMCDDA and international organisations (UNODC, 
WHO). Ultimately, the EU Member States will be asked to 
endorse and implement a set of indicators to monitor these 
three factors in the prison setting. ... In 2012, the EMCDDA 
will publish in its ‘Selected issues’ series a review of drugs 
and the prison setting.
New EMCDDA manual for prevention professionals
Reproduced from Drugnet Europe No. 71, 
July–September 2010
The EMCDDA’s Prevention and Evaluation Resources 
Kit (PERK) is a package of evidence-based prevention 
principles, planning rules and evaluation tips for prevention 
professionals. Until recently available only as an online 
product, this valuable resource has now been released as a 
printed EMCDDA manual. 
Available at www.emcdda.europa.eu/publications/perk
Drugnet Europe is the quarterly newsletter of the European 
Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), and is available at www.emcdda.europa.eu.
If you would like a hard copy of the current or future issues, 
please contact: 
Health Research Board
Knockmaun House 
42–47 Lower Mount Street 
Dublin 2 
Tel: 01 2345 148; Email: drugnet@hrb.ie
From Drugnet Europe
Pharmacy guidelines on safe supply of codeine-
based products
The Pharmacy Act 2007 and the Regulation of Retail Pharmacy 
Businesses Regulations 2008 require that all codeine-based 
products are dispensed under the supervision of a pharmacist, and 
that individuals in receipt of the product should receive appropriate 
counselling. In May 2010, the Pharmaceutical Society of Ireland 
published guidelines on the safe dispensing of non-prescription 
products containing codeine.1 Codeine is an opiate-based analgesic 
which is controlled under the Misuse of Drugs Acts 1977 and 1984 
and is most often sold as a combination drug in non-prescription 
medication. It is well established that codeine-based medications 
have the potential to be abused and, if used for long periods, 
psychological and physical dependence can occur. Withdrawal 
of codeine in individuals who have taken excess doses over long 
periods of time may result in restlessness and irritability. 
Codeine is used in many popular over-the-counter painkillers (e.g. 
Solpadeine), often in combination with other non-prescription 
painkillers such as paracetamol or ibuprofen (e.g. Nurofen Plus). 
Certain cough medicines and fl u remedies also contain codeine.2 
An individual who takes excess amounts of a combination drug is at 
risk of the toxic effects of both drugs.
The guide aims to ensure the safe supply of medicines and to 
support pharmacists in their legal obligation to dispense non-
prescription products containing codeine. The main points in the 
guide are: 
Products containing codeine cannot be displayed in the ‘self- ■
selection’ area of the pharmacy.
Codeine-based products should only be dispensed under the  ■
supervision of the pharmacist, who should be in a position to 
consult with the patient so as to determine the appropriateness 
of the request. Each repeated request should have a 
separate consultation.
Education should be provided to the individual in receipt of  ■
codeine-based products, including dosage regime, overdose 
risk, drug interactions, side effects and safe storage.
Pharmacists should be alert to the possibility that some patients  ■
may request codeine-based medicines for symptoms that are in 
fact secondary to excess codeine consumption.
Products containing codeine are a second-line treatment and  ■
should only be considered when the likes of paracetamol, 
aspirin and ibuprofen have not been successful in pain 
management.
It is the responsibility of the pharmacist to manage the supply  ■
and ensure suitable controls are in place for the management 
of dispensing codeine-based products.
If a pharmacist suspects that an individual is abusing or  ■
dependant on codeine, she/he is obliged to make a reasonable 
attempt to facilitate the individual in accessing treatment 
services.
Advertising medication containing codeine is prohibited;  ■
this includes window displays, in-pharmacy promotions, 
promotional displays and leafl ets and stickers.
(Simone Walsh)
1. Pharmaceutical Society of Ireland (2010) Non-prescription 
medicinal products containing codeine: guidance for pharmacists 
on safe supply to patients. Dublin: Pharmaceutical Society of 
Ireland. Available at www.drugsandalcohol.ie/13191
2. Irish Medicines Board (2010) Human medicine product list: 
codeine. Accessed 30 July 2010 at www.imb.ie 
drugnet 
IRELAND
29
On 6 April 2010 Social Justice Ireland published its Socio-
Economic Review for 2010 entitled ‘An agenda for a new 
Ireland’. The authors argue that Ireland’s policy-making 
for more than a decade was guided by false assumptions 
concerning economic growth, taxation, services and 
infrastructure, and that many policy failures arose from these 
false assumptions. They contend that Ireland needs a new 
vision to guide policy development and decision-making, 
and set out four core values that should underpin a guiding 
vision for Ireland – human dignity, sustainability, equality/
human rights, and ‘the common good’. www.socialjustice.ie 
On 7 May 2010 the Offi ce of the Minister for Children 
and Youth Affairs published a report Study of young carers 
in the Irish population. The researchers defi ned a young 
carer as ‘a child or young person under 18 years whose life is 
affected in a signifi cant way by the need to provide care for 
a family or household member who has an illness, disability, 
addiction or other care requirement’. The research team 
failed to recruit and interview children and young people 
of parents with drug or alcohol addictions, and concluded 
that, as a result, it was ‘likely that the fi nal sample does not 
include the most vulnerable categories of young carers’. 
www.omcya.ie 
In its editorial on 22 May 2010 The Lancet (Vol. 375, Issue 
9728) applauded US President Barack Obama’s fi ve-
year National Drug Control Strategy (NDCS), which was 
released on 11 May 2010: ‘Obama’s new plan is a welcome 
departure from the ideologically driven measures of previous 
administrations and from other countries such as the UK, 
which have failed on several occasions to use evidence as 
the basis of drugs policy.’ The NDCS aims to reduce the 
rate of youth drug use and the number of chronic drug 
users by 15% not only through law enforcement initiatives 
but also by strengthening efforts to prevent drug use in 
communities, improving early intervention opportunities 
in health care, integrating treatment for substance use 
disorders into health care, expanding support for recovery, 
and improving information systems. In 2010 the NDCS is 
focusing on three specifi c areas: preventing drug use, driving 
under the infl uence of drugs, and prescription drug abuse. 
The Lancet comments: ‘these are well-chosen priorities since 
those who reach 21 years without developing an addiction 
are less likely to do so afterwards, driving under the infl uence 
of illegal drugs is now more common than drunk driving in 
the USA, and the abuse of prescription drugs is the country’s 
most rapidly growing drug problem’. www.thelancet.com 
and www.ondcp.gov/policy/ndcs.html 
For 26 June 2010, International Day Against Drug Abuse 
and Illicit Traffi cking, the United Nations Offi ce on Drugs 
and Crime (UNODC) chose the theme ‘Think health, not 
drugs’. The intention is to raise awareness about the major 
challenge that illicit drugs represent to society as a whole, 
and especially to the young. The goal of the campaign is to 
mobilise support and to inspire people to act against drug 
abuse. The campaign encourages young people to put their 
health fi rst and not to take drugs. www.unodc.org 
On 6 July 2010 medicinal cannabis was the subject of a 
response to a written question in Dáil Éireann. Minister 
for Health and Children, Mary Harney TD, stated: ‘The 
current legal position in Ireland in relation to cannabis 
and cannabis based medicinal products such as Sativex is 
that they are Schedule 1 controlled substances under the 
Misuse of Drugs Act 1977. All Schedule 1 substances are 
substances which are considered as having no medicinal 
use and the manufacture, production, preparation, sale, 
supply, distribution and possession of cannabis and cannabis 
derivatives is unlawful except for the purposes of research. 
My Department is aware that claims have been made in 
respect of Sativex and its possible benefi ts for patients 
suffering from certain conditions such as Multiple Sclerosis 
and cancer. As the law currently stands it would not be 
possible for Sativex to be licensed here for medicinal use 
or for a General Practitioner to prescribe it. As cannabis is 
the drug which is most abused in Ireland, I am reluctant to 
loosen the controls on its use. However, I am seeking expert 
clinical advice in this matter and I am open to making a 
change to the Misuse of Drugs legislation to allow for the 
use of medicinal cannabis based drugs such as Sativex, 
if the expert advice indicates that a change is warranted.’ 
www.oireachtas.ie 
Between 18 and 23 July 2010 the XVIII International 
Aids Conference (AIDS 2010) was held in Vienna. The 
conference issued an offi cial declaration, the Vienna 
Declaration, which seeks to improve community health and 
safety by calling for the incorporation of scientifi c evidence 
into illicit drug policies. Drafted by a team of international 
experts, the Declaration states: ‘The criminalisation of illicit 
drug users is fuelling the HIV epidemic and has resulted in 
overwhelmingly negative health and social consequences. 
A full policy reorientation is needed … Reorienting drug 
policies towards evidence-based approaches that respect, 
protect and fulfi l human rights has the potential to reduce 
harms deriving from current policies and would allow for the 
redirection of the vast fi nancial resources towards where they 
are needed most: implementing and evaluating evidence-
based prevention, regulatory, treatment and harm reduction 
interventions.’ Scientists, health practitioners, organisations 
and the public around the world are being invited to 
endorse this document in order to bring these issues to the 
attention of governments and international agencies, and 
to illustrate that drug policy reform is a matter of urgent 
international signifi cance. www.viennadeclaration.com 
On 26 July 2010 the UK Drug Policy Commission (UKDPC) 
published The impact of drugs on different minority groups: 
a review of the UK literature. This review found that drug 
services were of ‘little relevance’ to many in Britain’s diverse 
communities, including LGBT (lesbian, gay, bisexual and 
transgender) groups, disabled people and BME (black 
and minority ethnic) communities. The authors argue 
that a better understanding of drug use within diverse 
minority communities is needed to reduce drug problems. 
Appropriate data-gathering and intelligence-sharing 
mechanisms could also be used to fl ag health risks associated 
with the use of new drugs within these groups before their 
use becomes widespread. www.ukdpc.org.uk 
(Compiled by Brigid Pike)
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Recent publications
On our shelves
Books recently acquired by the National 
Documentation Centre on Drug Use 
Benign anarchy: Alcoholics Anonymous in Ireland 
by Shane Butler
Publisher: Irish Academic Press
Date of publication: 2010
ISBN: 9780 7165 3064 0 (paper)
Journal articles
The following abstracts are cited from recently 
published articles relating to the drugs situation in 
Ireland.
What are the risk factors for soft tissue abscess 
development among injecting drug users? 
Maloney S, Keenan E and Geoghegan N
Nursing Times.net 2010; 106(23) 
www.drugsandalcohol.ie/13439
Background: Much research has been conducted 
on the risk taking behaviour of injecting drug 
users. Cutaneous or subcutaneous skin and soft 
tissue abscesses are common complications of 
intravenous drug use.
Aim: To identify the risk factors to which injecting 
drug users expose themselves to improve initial 
assessment.
Method: A convenience sampling method was 
used, and structured interviews were carried 
out with 70 injecting drug users attending a 
methadone treatment setting in Dublin.
Results and discussion: Forty-eight (69%) 
participants have had an abscess at some stage. 
Poor levels of skin cleansing were identifi ed as a 
main cause, and 80% admitted to sharing injecting 
equipment.
Conclusion: Healthcare professionals need to 
develop better strategies for delivering safety 
messages to clients about safer injecting behaviour.
Longitudinal outcomes for treated opiate use 
and the use of ancillary medical and social 
services
Comiskey C and Stapleton R
Substance Use & Misuse 2010; 45(4): 628–641 
www.drugsandalcohol.ie/13079 
Using an extended Maudsley Addiction Profi le, 
404 opiate users entering treatment across Ireland 
were interviewed at intake, at one year and at 
three years between 2003 and 2006. At three years 
clients were abstinent, in treatment, or relapsed. 
Analysis of lifetime use of treatment services 
revealed that greater proportions of those who 
were drug free at three years had had counselling 
in the past. Multiple regression revealed that the 
number of previous treatment episodes had a 
signifi cant positive effect on outcomes. Findings 
are important during times of fi nancial constraint, 
when treatment providers are under pressure to cut 
back to core services.
Cannabis and hyperemesis 
Harris E, McDonagh M and Kennedy N 
Irish Journal of Psychological Medicine 2010; 27(1): 47–48
www.drugsandalcohol.ie/12950
The adverse effects of marijuana are well 
documented, as well as its positive therapeutic uses. 
Cannabis has traditionally been associated with an 
antiemetic action following acute ingestion and 
synthetic cannabinoids have an established use as 
anti-emetics for chemotherapy induced nausea. 
However, there has been limited recognition of 
chronic cannabis use as a cause of cyclical vomiting 
syndrome. Cannabinoid hyperemesis was fi rst 
identifi ed by Allen et al in 2004. Compulsive 
bathing was also described as part of the clinical 
picture. This same syndrome has been confi rmed 
a number of times .in the medical literature in the 
interim. The condition has, to our knowledge, 
never been reported, in a psychiatric patient.
Absinthe and suicidality 
Rizvi N, Whitty M and Daly R
Irish Journal of Psychological Medicine 2010; 27(1): 44–45
www.drugsandalcohol.ie/12951
Absinthe is an alcoholic drink which is becoming 
more widely consumed after being banned 
for many decades. An association between 
absinthe use and psychiatric symptoms, ranging 
from impairment of concentration to marked 
hallucinations and seizures, has been suggested, 
but evidence remains unclear. Thujone, identifi ed 
as a possible psychoactive ingredient, has 
recently been implicated in absinthe’s putative 
neuropsychiatric effects. This report presents a case 
where acute suicidality emerged during absinthe 
consumption; possible neurobiological aetiological 
mechanisms and the history of absinthe use and 
associated adverse effects are reviewed.
Suppression effects of partner type on the 
alcohol-risky sex relationship in young Irish adults 
Cousins G, McGee H and Layte R 
Journal of Studies on Alcohol and Drugs 2010; 71(3): 
357–365 www.drugsandalcohol.ie/13412
Objective: The present study examined the link 
between alcohol consumption and condom use, 
testing whether partner type suppresses the effects 
of alcohol consumption on condom use. This study 
also sought to determine whether the effects of 
alcohol on condom use during casual sex remain 
after adjusting for condom-use intentions and 
planning or preparatory behaviors, such as having a 
condom available. 
Method: A retrospective, cross-sectional study 
design was used. A subset of participants aged 
19–30 years from the national Irish Study of Sexual 
Health and Relationships were recontacted (n = 
388). Telephone interviews regarding participants’ 
most recent sexual event in their normal social 
drugnet 
IRELAND
31
environment (i.e., not on holidays) were conducted (n = 
362). Partnership type was defi ned as ‘just met’, ‘casual’ or 
‘steady’. Men comprised 51% of the sample. The mean age 
was 23.9 years. 
Results: Both alcohol consumption and condom use were 
more common in casual sexual events than steady sexual 
events. In addition, partnership type was found to suppress 
the effects of alcohol consumption on condom use, such that 
the relationship between alcohol consumption and condom 
use became signifi cant and negative only after controlling 
for partner type. Furthermore, the negative effects of alcohol 
consumption on condom use during casual sex remained after 
adjusting for condom-use intentions and planning. 
Conclusion: These fi ndings illustrate the complexity of the 
relationship between alcohol consumption and condom use, 
highlighting the importance of contextual factors such as 
partner type. Furthermore, the effects of alcohol on condom 
use during casual sex cannot be explained by the fact that 
such events tend to be more spontaneous and less planned.
Deliberate self-harm (DSH) out of hours presentation 
McNicholas F, O’Sullivan M, Lennon R, Doherty M and 
Adamson N
Irish Journal of Psychological Medicine 2010; 27(1): 11–14
www.drugsandalcohol.ie/12952
Objective: To establish time of presentation to paediatric 
accident and emergency (A&E) services of children with 
deliberate self-harm (DSH). 
Method: All children presenting to an acute paediatric 
hospital with DSH or suicidal ideation between 1993–2003 
were identifi ed and time of presentation collected from their 
case notes.
Results: Of the 172 children where the actual time of 
presentation was recorded, 137 (80%) presented to the 
hospital outside of the ‘normal working hours’ of 9am–5pm, 
Monday–Friday. These children represent an at-risk group, 
and were more likely to have consumed alcohol, to have 
made a suicide attempt, and to have a family history of 
psychiatric illness than children presenting within normal 
working hours.
Conclusion: DSH in young people is a signifi cant public 
health problem in Ireland and is a major risk factor for 
completed suicide. Access to an out-of-hours, on-call 
Child and Adolescent Psychiatry (CAP) services is essential 
if these children are to have a mental health assessment, 
as recommended by the Royal College of Psychiatry and 
National Institute of Clinical Excellence. These services need 
to be urgently developed.
(Compiled by Joan Moore; jmoore@hrb.ie)
September 
9 September – 23 October 2010
Dublin 8 Art by Dublin 8 Artists
Venue: National College of Art and Design, Thomas Street, 
Dublin 8
Organised by / Contact: RADE (Recovery through arts, drama 
and education) www.rade.ie
Information: On 9 September RADE will launch ‘Portraits’, a 
collection of the group’s creative writing stories, facilitated by 
poet Paula Meehan, along with their fi rst ever Retrospective Art 
Exhibition showcasing artwork from the past fi ve years. This will 
be RADE ‘s fi rst time showcasing their work in the NCAD and we 
are delighted with the freedom and space that has been allowed 
to us. We are also thrilled that for the fi rst time ever we are able 
to display the artistic talents of the different groups that have 
been in RADE since the organisations fi rst exhibition in 2005. 
The showcase runs until 23 October.
23 September 2010
Shifting Focus: from Criminal Justice to Social Justice
Venue: Gresham Hotel, Dublin 1
Organised by / Contact: Irish Penal Reform Trust, Barnardos 
and the Irish Association of Young People in Care (IAYPIC)
Email: info@iprt.ie www.iprt.ie
Information: At a time of a deepening economic and social crisis, 
we want to propose a simple yet proven idea – that a shift in 
resources from criminal justice to social justice makes social and 
economic sense. Informed by a common commitment to human 
rights and social justice, IPRT has come together with Barnardos 
and IAYPIC to analyse how this idea can be put in practice.  
To this end, we will host a one-day conference to consider how 
Ireland might begin to refocus our approach to crime and social 
policy in line with these principles. The conference will hear 
from leading Irish and international speakers, who will address 
the social and economic dimensions of crime, and explore the 
theory and practice of how interventions can be designed to 
achieve effective results. 
27 September 2010
Together – Making A Difference
Venue: Liberty Hall Theatre, Eden Quay, Dublin 1
Organised by / Contact: North Inner City Drugs Task Force
Email: admin@nicdtf.ie; tel: 01 8366 592 www.nicdtf.ie
Information: The theme of this one-day conference is: 
Responses to drugs problems for individuals, family and 
communities – contexts, achievements, challenges. The event 
will include: 
Exhibits and information about NICDTF projects and actions; ■
Recorded and live short displays of local involvement; ■
A panel discussion among community activists on the North  ■
Inner City in the last 15 years;
Comments on local actions and national drugs strategies  ■
from Minister Pat Carey TD, NICDTF Chair Joe Barry and 
community/NGO activists.
October 
9–10 October 2010
Family Support Network Annual Work Conference
Venue: Fairways Hotel, Dundalk
Organised by / Contact: Family Support Network
Email: info@fsn.ie; tel: (01) 836 5168 www.fsn.ie
Information: The FSN Annual Work Conference brings together 
members of family support groups and individual family 
members living with drug use. Over 350 family members attend 
on an annual basis. The conference is an opportunity 
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for family members to discuss and inform themselves on the 
different issues affecting their lives as a result of drug use. This 
year’s conference will include discussion of national policy 
developments and training workshops. A key element of the 
conference is that it provides respite for family members and 
this is supported by family members volunteering their time 
to provide holistic therapies. If you would like to volunteer to 
provide holistic therapies during the conference please call 
Megan on (01) 836 5168. 
11–17 October 2010
Cork Drug Awareness Week 2010
Venue: Various community / city-wide venues in Cork 
Organised by: Cork Local Drugs Task Force Projects 
Email: Gemma.OLeary@hse.ie mmagee@partnershipcork.ie 
www.corkcitypartnership.ie for detailed schedule of the week. 
Cork Local Drugs Task Force website will be re-launched during 
the week. 
Information: The aim of Cork Drug Awareness Week is to raise 
awareness and signpost information so that communities, 
families and individuals know where to go for information and 
support on drug and alcohol issues. Various Cork Local Drugs 
Task Force projects are organising information events / coffee 
mornings / holistic therapies etc. in community settings across 
the city throughout the week. The programme includes events 
for youth, families, parents, and minority communities. Mark 
Johnson (author of ‘Wasted’) is a featured speaker. Topical DVDs 
will be screened and a memorial event for those how have lost 
family members or friends to drugs or alcohol will also take 
place. Topics covered by speakers include heroin, prescription 
drugs and family support, among others. 
15 October 2010
A Community Drug Problem: defi ning the problem – defending 
the responses
Venue: St Andrews Resource Centre, Pearse Street, Dublin 2
Organised by / contact: CityWide Drugs Crisis Campaign
Email: info@citywide.ie; tel: 01 836 5090/ 01 836 5039
www.citywide.ie
Information: This conference is an opportunity for those 
working in local community projects and groups to come 
together with local and regional drugs task force community 
representatives to discuss some of the key issues facing 
communities responding to the continuing drugs crisis. Minister 
Pat Carey will open the conference. Our key note speaker is 
Brian Harvey, who has just completed research on the impact of 
the last budget on the community and voluntary sector. He will 
address this conference specifi cally on the impact of government 
cuts on communities and community drugs services.
The conference is divided into three main sections:
Engaging ‘communities of interest’ locally, regionally and  ■
nationally in service provision and policy development
Challenges for communities with the Alcohol Strategy roll-out  ■
and fi ndings in one area of changing patterns of drug use
Community safety – overview of local, national and  ■
international responses.
November
4–5 November 2010
National Drugs Conference: Continuum of care within drug 
services
Venue: Radisson Blu Royal Hotel, Dublin 8
Organised by / Contact: Irish Needle Exchange Forum (INEF) 
and others
Email: conference2010@inef.ie 
http://inef.ie
Information: See p. 1 of this issue. 
17 November 2010 
Addiction: the case for recovery in a changing world 
Venue: Congress Centre, London W1B 3LS
Organised by / Contact: Medineo for Medical Events
Tel: +357 25 878844 
www.medineo.org
Information: This conference will look at the evidence base to 
support recovery and to inform the fi eld on what it takes to build 
recovery capital in our towns and cities. Leaders in the fi eld will 
discuss the evidence base for drug and alcohol recovery models 
and what the implications are for therapeutic interventions. 
Using examples of best practice we will explore how drug 
treatment systems can gear up for the increased demand for 
recovery options from the public; the political support for 
recovery options and how to make this possible within the 
economic climate. We will also look at how new political drivers 
and the economic context plays in to this agenda and will build 
the economic argument for ensuring that drug and alcohol 
treatment systems include viable recovery options.
May 2011
23–24 May 2011
Fifth annual ISSDP conference
Venue: Utrecht, The Netherlands
Organised by / Contact: International Society for the Study of 
Drug Policy (ISSDP) / Alex Stevens
Email: enquiries@issdp.org www.issdp.org
Information: Further information about the conference and a call 
for abstracts will be available on the society’s website in due course.
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